

1 Altered cortical network in Parkinson's 2 Disease: the central role of PV interneuron and 3 synaptic remodelling

4 Antea Minetti,^{1†} Elena Montagni,^{1,2†} Nicolò Meneghetti,^{3,4†} Francesca Macchi,¹ Éléa Coulomb,^{1,5},
5 Alessandra Martello,^{1,6} Alexia Tiberi,^{1,6} Simona Capsoni,⁷ Alberto Mazzoni,^{3,4} Anna Letizia Allegra
6 Mascaro,^{1,2} Cristina Spalletti^{1*}

7 ¹ Neuroscience Institute, National Research Council (CNR); 56124, Pisa, Italy.

8 ² European Laboratory for Non-Linear Spectroscopy (LENS); 50019, Sesto Fiorentino, Italy.

9 ³ The Biorobotics Institute, Scuola Superiore Sant'Anna; 56025, Pisa, Italy.

10 ⁴ Department of Excellence for Robotics and AI, Scuola Superiore Sant'Anna, Pisa 56025, Italy.

11 ⁵ Bio@SNS Laboratory of Biology, Scuola Normale Superiore, 56126 Pisa, Italy.

12 ⁶ Interdisciplinary Health Science Center, Scuola Superiore Sant'Anna; 56025, Pisa, Italy. ⁷ Section of Human
13 Physiology, Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara 44121, Italy.

14 †Equal contribution as first author.

15 *Correspondence: cristina.spalletti@in.cnr.it

16 **ABSTRACT**

17
18 Parkinson's disease (PD) is traditionally defined by the progressive degeneration of nigrostriatal
19 dopaminergic neurons; however, accumulating evidence highlights extensive cortical dysfunctions as
20 key contributors to motor and non-motor symptoms. Despite this growing recognition, the precise
21 mechanisms underlying cortical network disruptions and their contribution to PD pathophysiology
22 remain poorly understood, particularly in relation to parvalbumin-positive interneurons (PV-INs) and
23 maladaptive plasticity. Here, we investigate the dysregulation of cortical network homeostasis in PD
24 using a 6-hydroxydopamine (6-OHDA) mouse model, focusing on the progressive disruption of
25 parvalbumin-positive interneuron (PV-IN) connectivity, excitatory/inhibitory balance, and
26 neuroinflammatory responses. Using a multimodal approach integrating longitudinal electrophysiology,
27 wide-field calcium imaging, and histological analyses, we revealed striking alterations in cortical activity
28 and connectivity. Specifically, we observed pathological high-gamma hyperactivity during movement,
29 accompanied by severe disruptions in PV-IN connectivity across motor and somatosensory cortices.
30 Histological analyses further revealed synaptic imbalances and microglial dysregulation, suggesting an
31 extensive cortical response to dopaminergic loss. These findings indicate that PV-IN dysfunction drives
32 cortical maladaptive plasticity, leading to network desynchronization and motor deficits. By reframing
33 PD as a disorder of cortical network homeostasis, this study provides novel mechanistic insights and
34 identifies cortical plasticity as a promising therapeutic target for disease modification.

35 **KEYWORDS**

36
37 Cortical oscillations; Network remodeling; Neuroinflammation; Dopaminergic degeneration; synaptic
38 plasticity; inhibitory system.

39 **INTRODUCTION**

40
41 Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder that primarily affects
42 the motor system, impacting millions of individuals worldwide [1]. The hallmark of PD is the
43 degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the subsequent
44 depletion of dopamine in the striatum. This dopamine deficiency disrupts the basal ganglia circuitry,
45 leading to the characteristic motor symptoms of PD, including tremors, rigidity, bradykinesia, and
46 postural instability [1–3].

47
48 Emerging evidence underscores the central role of dysfunctions within the basal ganglia-thalamo-
49 cortical network in PD pathology. This network is critical for motor control, and its alterations profoundly
50 affect the motor cortex, a region essential for voluntary movement and a promising target for therapeutic
51 interventions [4–6]. A key feature of network dysfunctions is the disruption of cortical and subcortical
52 oscillatory activity. Gamma-band oscillations, in particular, are crucial for motor planning and execution,

53 as they facilitate neuronal synchronization and communication within the motor cortex [7]. Notably, PD
54 patients exhibit a marked reduction in gamma-band oscillations within the basal ganglia-thalamo-
55 cortical network, which correlates with motor dysfunction and symptom severity [8].

56 The generation and maintenance of gamma-band oscillations depend heavily on GABAA receptor-
57 mediated inhibition, primarily governed by parvalbumin-expressing interneurons (PV-INs) [9]. PV-INs
58 are fast-spiking GABAergic cells that provide strong perisomatic inhibition to pyramidal neurons,
59 regulating cortical network activity, excitatory-inhibitory (E/I) balance, and synchronized oscillatory
60 rhythms [10–12]. Dopamine depletion has been shown to rapidly reduce PV expression in the striatum,
61 suggesting early synaptic dysfunction in PV-INs [13]. Despite growing evidence linking PV-IN
62 dysfunction to basal ganglia pathology, the impact of dopamine depletion on cortical PV-INs and the
63 mechanisms underlying cortical network remodeling in PD remains poorly understood.

64 Here, we provide a comprehensive functional and anatomical characterization of cortical dysfunctions
65 in a 6-hydroxydopamine (6-OHDA) mouse model of PD. By combining longitudinal electrophysiological
66 recordings, wide-field calcium imaging, and histological analyses, we investigate how dopaminergic
67 degeneration affects PV-IN network connectivity, excitatory/inhibitory balance, and neuroinflammatory
68 responses.

69 We revealed heightened synchronization in the delta band in striatum over time and increased high-
70 gamma band modulation in motor cortex during voluntary movements.

71 This progressive breakdown of cortical network integrity is paralleled by disruptions in the cortical PV-
72 IN network, particularly at later stages of pathology progression. These alterations were associated with
73 synaptic remodeling, excitatory/inhibitory imbalance of cortical vesicular markers and heightened
74 microglial phagocytic activity in the motor cortex.

75 These findings redefine PD as a network disorder and highlight the potential for cortical plasticity
76 modulation as a therapeutic strategy. Understanding these mechanisms may open new avenues for
77 developing interventions aimed at restoring cortical homeostasis and mitigating disease progression.

78

79 **METHODS**

80

81 ***Animals***

82 Adult wild-type male C57BL/6J mice (3–4 months old; RRID: IMSR_JAX:000664) were used for
83 electrophysiological and histological analyses (n=8 CNT and n=13 6-OHDA). Adult homozygous PV-
84 Cre knock-in mice (2-3 months old; RRID: IMSR_JAX:008069), were used for wide-field imaging
85 analysis and histological analyses (n=5 CNT and n=4 6-OHDA). Mice were housed up to four animals
86 per cage under a 12-hour/12-hour light/dark cycle with access to food and water *ad libitum*. All
87 experimental procedures respected the ARRIVE guidelines and the European Communities Council
88 Directive #86/609/EEC were approved by the Italian Ministry of Health Autorizzazione n° 544/2023-PR
89 (Risp. a prot. B4BB8.43).

90

91 ***6-OHDA Injection***

92 To induce a Parkinsonian model, intra-striatal injections of 6-hydroxydopamine (6-OHDA) were
93 performed. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed in
94 a stereotaxic frame. The right striatum was targeted using the following coordinates relative to bregma:
95 anterior-posterior (A/P) +1.0 mm, mediolateral (M/L) -1.8 mm, and dorsoventral (D/V) -3.2 mm. A
96 Hamilton syringe with a fine glass capillary was used to inject 6 mg/mL 6-OHDA dissolved in ascorbic
97 acid solution (0.02% mg/mL) in sterile saline at a rate of 0.2 μ L/min for a total volume of 2 μ L [14–16].
98 Control mice received the same volume of physiological saline and ascorbic acid solution.

99

100 ***Electrophysiological Recordings***

101 *Surgery:* Stainless steel bipolar electrodes were implanted immediately following the 6-OHDA injection.
102 The striatal electrode, targeting the striatum (CPu), was positioned at the same coordinates as the toxin
103 injection, but at a depth of 4 mm. The cortical electrode was inserted 1 mm posterior to the striatal
104 electrode, maintaining the same mediolateral coordinate. This cortical electrode was 1 mm in length,

105 sufficient to reach the superficial layers of the primary motor cortex (M1). An additional hole was drilled
106 at the center of the occipital bone to facilitate the insertion of a surgical screw, which served both as a
107 ground reference and to provide additional stability to the recording implant. The two bipolar electrodes
108 were then soldered to the pins of a connector. The ground pin was connected to the occipital screw,
109 and a first layer of dental cement (Super Bond CeB, Sun Medical Co., Japan) was applied to secure all
110 components to the skull surface. Once the first layer of cement had dried, a second layer (Paladur,
111 Pala, Germany) was applied to enclose the electrical components. To assure a proper head fixation of
112 the animal, crucial for task performance and signal quality during recordings, an L-shaped metal bar
113 (0.6 g) was also attached to the occipital bone using dental cement Super Bond. Following surgery,
114 glucose and paracetamol were administered, and the mice were allowed to recover. After all surgical
115 procedures, animals were carefully stitched and treated with intra-operative analgesia (tramadol 10
116 mg/kg) and intramuscular injection of cortisone (Bentelan 0.05 ml) upon waking from anesthesia. As a
117 further analgesic, paracetamol (100 mg/kg) was administered for 4 days post-operation in drinking
118 water. The implant enabled simultaneous recordings of neuronal activity in the striatum and motor
119 cortex of the ipsilateral hemisphere relative to the dopaminergic lesion. Electrophysiological recordings
120 were performed during both rest and motor tasks, beginning in the first week post-lesion and continuing
121 until the fourth week.

122 *M-Platform for Forelimb Retraction Task:* The M-Platform is a robotic system developed in our
123 laboratory for upper limb exercise in mice [17, 18]. It consists of a linear actuator (Micro Cylinder RCL,
124 IAI Germany), a 6-axis load cell (Nano 17, ATI Industrial Automation USA) with a controlled friction
125 system, and a custom-designed handle fixed to the left forelimb positioned on a precision linear sled
126 (IKO BWU 25-75, USA). One end of the handle is screwed onto the load cell for force transfer to the
127 sensor, while the other end serves as a support for the animal's wrist [19]. *Electrophysiological*
128 *recordings at rest:* After 24 hours of recovery, mice were acclimated to the head restraining system on
129 the M-Platform. Weekly training sessions were conducted for both resting-state and motor task
130 recordings. For resting-state recordings, mice were head-fixed on the M-Platform, with the left forepaw
131 linked to the load cell but without performing the forelimb retraction task. This configuration minimized
132 voluntary movements, allowing the acquisition of neuronal activity exclusively in the ipsilateral
133 hemisphere during rest and excluding any movements sensed by the M-Platform. The chronic recording
134 setup included two bipolar electrodes for simultaneous local field potential (LFP) recordings in the
135 striatum and motor cortex. Signals were amplified using a DigiAmp (Plexon, USA) and referenced to a
136 ground electrode placed at the cerebellum. Data acquisition was performed using the OmniPlex D
137 Neural Data Acquisition System (Plexon Inc., USA). Resting-state signals were recorded for three
138 minutes in an awake but stationary state.

139 *Electrophysiological recordings during voluntary motor task:* Following the resting-state recordings,
140 mice performed the forelimb retraction task, during which LFP signals from the striatum and motor
141 cortex were recorded. Each session consisted of 15 forelimb retractions, alternating between passive
142 (device-extended by 10 mm) and active (animal-retracted) movements. A sugar water reward was
143 provided for each successful task completion, contingent on surpassing a defined force threshold. Mice
144 typically mastered the task within 2-3 days. [17] Task friction was adjusted based on individual functional
145 deficits. Electrophysiological signals were recorded throughout the task to capture neural activity in the
146 ipsilateral hemisphere during the motor performance. A high-resolution camera (Zyno Full HD, Trust
147 Netherlands, 25 Hz) was positioned parallel to the coronal plane of the animal, capturing video footage
148 synchronized with load cell force signals. Position and velocity signals were extracted from the video
149 and aligned with force signals using a custom algorithm developed in Matlab (MathWorks, USA)
150 (Spalletti et al., 2014). NeuroExplorer software was used to process power spectral density (PSD) data
151 during the task and LFP signals associated with force peaks. Offline analyses, performed with custom
152 algorithms in NeuroExplorer and Matlab, included PSD computation and synchronization of neural and
153 force signals. This setup enabled detailed analysis of cortical and striatal activity during both resting
154 and motor task conditions, providing insights into the neuronal dynamics associated with the lesion-
155 induced motor deficits.

156

157 **Electrophysiological Recordings Data Analysis**

158 *LFP extraction and spectral analysis at rest:* From extracellular recordings during the resting state, local
159 field potentials (LFPs) were extracted by applying a low-pass filter at 200 Hz. The LFP signals were
160 then z-scored prior to spectral analysis to normalize the data. Recordings with excessive signal
161 deflection exceeding ± 5 SD of the mean were removed from further analyses. The power spectral
162 density (PSD) of the z-scored LFPs was calculated using the Fast Fourier Transform (FFT)
163 implemented via the Welch method (using the `pwelch` function in MATLAB). For this analysis, the time
164 window of interest was divided into 10-second sub-windows with 50% overlap to improve spectral
165 estimation. Frequency bands of interest were defined as follows: delta (2.5-5.5 Hz), beta (13-30 Hz),
166 and gamma (30-60 Hz), and their respective power was computed as the average PSD within these
167 frequency ranges. For the resting-state analysis we excluded from the LFPs those signals' portions
168 contaminated by animal movements.

169 *Coherence Analysis at rest:* The magnitude-squared spectral coherence between striatal and cortical
170 LFPs was estimated using the `mscohere` function in MATLAB. This function computes the coherence
171 as the ratio between the magnitude-squared cross-power spectral density of the two signals and the
172 product of their individual PSDs.

173 *Cross-correlation of Delta Power Fluctuations at rest:* To investigate functional connectivity, we
174 computed the cross-correlation between delta power fluctuations of the striatal and cortical LFPs using
175 the `xcorr` function in MATLAB. Delta power fluctuations were estimated by applying a Hilbert transform
176 to the delta-filtered signal, and then taking the absolute value of the resulting signal to obtain the
177 envelope of the delta activity.

178 *Time-frequency analysis of motor task LFPs:* To analyze the temporal evolution of spectral patterns in
179 LFPs during motor tasks, we performed time-frequency decomposition using wavelet analysis. LFP
180 scalograms were generated via continuous wavelet transform (MATLAB `cwt` function) with the analytic
181 Morse wavelet, setting the symmetry parameter to 3 and the time-bandwidth product to 60 for optimal
182 resolution. The entire LFP recording was subjected to wavelet transformation, and the resulting time-
183 frequency scalograms were segmented into windows spanning from -1500 ms to +500 ms relative to
184 movement onset. For normalization, scalograms were baseline-corrected using a reference period
185 between -1500 ms and -750 ms before movement onset. We specifically examined movement-related
186 power modulation in the delta (2.5-5.5 Hz) and high-gamma (100-150 Hz) frequency bands. These were
187 extracted from the scalograms within the [0, 250 ms] window post-movement onset to capture task-
188 related neural activity.

189 *M-Platform parameters extraction for motor task:* the M-platform parameter extraction was calculated
190 as previously shown in [17]. Briefly, task-related variables were derived from position, speed, and force
191 signals, including the mean force, calculated as the average force from peaks detected during sub-
192 movements, and the area under the force curve (AUC), which represents the total force exerted over
193 time during movement.

194 *Statistical analysis:* The statistical significance of power, coherence, correlation, and power modulation
195 was evaluated using a two-way ANOVA. The analysis included two factors: recording weeks and animal
196 group (6-OHDA vs CNT). The tests were applied to datasets containing multiple recordings per week
197 across animals, without averaging data at the animal level prior to statistical analysis. To further explore
198 differences between groups, post-hoc pairwise comparisons were conducted between the two animal
199 groups at each recording week using the Wilcoxon rank-sum test, allowing for non-parametric
200 evaluation of group differences.

201 **Wide-Field Imaging**

203 *Surgery:* PV-Cre mouse line, in which Cre recombinase is selectively expressed under the control of
204 the parvalbumin (PV) promoter, underwent wide-field imaging. For parvalbumin-expressing
205 interneurons (PV-INs) labeling with GCaMP7f, the Cre-dependent viral construct ssAAV-PHP.eB/2-
206 hSyn1-chI-dlox-jGCaMPf(rev)-dlox-WPRE-SV40p(A) (1.3×10^{13} vg/ml, volume: 50 μ L, Viral Vector
207 Facility, ETH, Zurich) was diluted in 100 μ L of saline solution. A final volume of 150 μ L was intravenously
208 injected in the retro-orbital sinus of PV-Cre mice under isoflurane anesthesia at P60 to allow wide-brain

209 infection. [20] Two weeks after AAV injection, mice were injected with either 6-OHDA (n=4) to induce a
210 parkinsonian model or vehicle (n=5) for control conditions. Immediately following the injection, the mice
211 underwent an intact-skull preparation to provide direct optical access to the cortex (modified from
212 Montagni et al., 2024 [21]). The surgery was performed under a cocktail of ketamine/xylazine (100/10
213 mg/kg i.p.). The skin and the periosteum were removed. Bregma was marked for stereotactic reference.
214 A custom-made aluminum head-bar placed behind lambda was glued to the skull using transparent
215 dental cement (Super Bond C&B – Sun Medical). The exposed skull was then covered with a thin layer
216 of the same cement.

217 *Wide-field microscopy setup:* Imaging was performed on the intact skull of the awake head-fixed animal
218 using a custom-made microscope setup. To excite the GCaMP7f indicator, a 470 nm light beam (LED,
219 M470L3, Thorlabs) filtered by a bandpass filter (469/17.5 nm, Thorlabs) is directed by a dichroic mirror
220 (MD498, Thorlabs) onto the objective lens (TL2X-SAP 2X Super Apochromatic Microscope Objective,
221 0.1 NA, 56.3 mm WD, Thorlabs). The fluorescence signals was selected by a bandpass filter (525/50
222 nm filter, Semrock, Rochester, New York, USA) and collected by a CMOS camera (ORCA-Flash4.0 V2
223 Digital CMOS camera / C11440-22CU, Hamamatsu). Images are acquired with 9 ms exposure time in
224 External Edge mode at 50 Hz for 6000 total frames with a resolution of 512x512 pixels and a field of
225 view (FOV) of 1.15x1.15 cm (depth 16-bit).

226 *Habituation and awake imaging:* One week after the surgery mice were acclimated to the head-fixation
227 for 5-4 days (10 min a day/mouse) to gradually reduce anxiety and abrupt movements prior to data
228 collection. Head-fixed imaging sessions were performed at 14, 21 and 28 days post lesion (DPL). Each
229 imaging session involves 5 recordings (180 s-long) of spontaneous cortical activity in awake, resting-
230 state mice.

231 *Image processing and data analysis:* All analyses were performed in MATLAB. Each imaging session
232 was registered using custom-made software, by taking into account the bregma and λ position. An
233 animal-specific field of view template was used to manually adjust the imaging field daily. To dissect
234 the contribution of each cortical area, we registered the cortex to the surface of the Allen Institute Mouse
235 Brain Atlas (www.brain-map.org) projected to our plane of imaging. For each block, image stacks were
236 processed to obtain the estimates of $\Delta F/F_0$. $\Delta F/F_0$ was computed for each pixel by using the equation
237 $\Delta F/F_0 = (F - F_0)/F_0$, with F representing fluorescence at a given time and F_0 the mean fluorescence
238 [21, 22]. The field of view was then downsampled to 128x128 pixels. Global signal regression (GSR)
239 was applied and a total of 22 ROIs were then selected (11 ROI for each hemisphere, 5x5 pixels)
240 representing key cortical regions. Correlation mapping was done for each subject by computing
241 Pearson's correlation coefficient between the average signals extracted from each ROI, with that of
242 each other ROI. The single-subject correlation maps were transformed using Fisher's r-to-z transform
243 and then averaged across all animals. Averaged maps were re-transformed to correlation values (r-
244 scores) for figure purpose. For each mouse, $r(\text{CNT})-r(6\text{-OHDA})$ was calculated and averaged across
245 mice in order to visualize matrices of difference between mice injected with vehicle or 6-OHDA.

246 The abbreviations and extended names for each areas are as follows: MOs-a, anterior region of
247 secondary motor cortex; MOs-p, posterior region of secondary motor cortex; MOp-a, anterior region of
248 primary motor cortex; MOp-p, posterior region of primary motor cortex; SSp-bfd, primary somatosensory
249 area, barrefield; SSp-tr, primary somatosensory area, trunk; SSp-fL, primary somatosensory area,
250 forelimb; SSp-hl, primary somatosensory area, hindlimb; RSP, retrosplenial cortex; VISa, associative
251 visual cortex; VISp, primary visual cortex. Throughout the text and figures, suffixes L and R were added
252 to denote cortical areas of the left or right hemisphere, respectively (e.g., RSP_L , RSP_R).

253 *Statistical analysis:* Network Based Statistic (NBS) Toolbox in MATLAB was used to statistically assess
254 functional network connectivity. [23, 24] We tested for both significantly higher and lower correlations.
255 Differences were considered significant at $p < 0.05$.

256

257 **Schallert Cylinder Test**

258 Schallert Cylinder Test was conducted weekly starting from the first week post 6-OHDA injection to
259 assess disease progression [16]. The Cylinder Test is highly effective for assessing unilateral
260 sensorimotor and motor dysfunctions. Animals are placed inside a Plexiglas cylinder (8 cm in diameter,

261 15 cm in height) adapted for mice according to the protocol described by Schallert and Tillerson. [25]
262 Each animal is recorded for five minutes using a camera (SMXF50BP/EDC, Samsung, Seoul, South
263 Korea) positioned beneath the cylinder. Videos are analyzed frame by frame to count the number of
264 forepaw touches on the cylinder wall. Specifically, the first paw touch on the cylinder walls and the
265 subsequent placement of the forelimbs back on the cylinder base are recorded [18]. To quantify the
266 number of touches made with the limb contralateral to the injection site, the % Contralateral Forelimb
267 was calculated as the ratio of the number of touches made with the forelimb contralateral to the lesion
268 while the animal climbs vertically within the cylinder to the total number of touches. [26]
269

270 **Histology**

271 Mice were deeply anesthetized with chloral hydrate and perfused transcardially with 4%
272 paraformaldehyde (PFA, Electron Microscopy Sciences) in 0.1M phosphate buffer. Extracted brains
273 were post-fixed in 4% PFA for 2 hours, followed by 30% sucrose in phosphate buffer at 4°C. Brains
274 were sectioned coronally at 50 µm using a sliding microtome (Leica, Germany) and maintained in PBS
275 for free-floating immunostaining.

276 For immunostaining, brain slices were incubated in a blocking solution for 1 hour at room temperature
277 (10% donkey serum; 0.3% Triton X-100 in PBS), treated with primary antibodies, prepared at the proper
278 concentration in 1% donkey serum and 0.2 % Triton X-100 in PBS overnight at 4°C. Following 3 washes
279 in PBS, the sections were incubated for 2 hours at room temperature with the specific secondary
280 antibodies. For nuclei visualization Hoechst dye (#B2883; 1:500; Bisbenzimidazole, Sigma Aldrich, USA).
281 Immunohistochemical analysis was conducted on the substantia nigra pars compacta and striatum
282 using primary anti-tyrosine hydroxylase (1:500 TH, INVITROGEN PA5-85167) and corresponding
283 secondary antibodies for detection of unilateral dopamine degeneration and confirm lesion presence.
284 Cortical plasticity markers such as parvalbumin, PV (1:500, SYSY 1950004); vesicular glutamate
285 transporter type 1, VGLUT1 (1:500, SYSY 135304); vesicular glutamate transporter type 2, VGLUT2
286 (1:500, SYSY 135403); and vesicular GABA transporter, VGAT (1:500, SYSY 131005) were also
287 investigated in primary motor cortex, particularly vesicular markers in superficial layer II/III. Microglial
288 cells and phagosomes in the cortex were stained respectively with rabbit anti-Iba1 1:500 (Wako, Osaka,
289 Japan, 019–19741) and rat anti-CD68 1:250 (BioRad, #MCA1957).

290 *Dopaminergic lesion analysis:* TH⁺ fibers signal was acquired using a Zeiss Axio Observer microscope
291 equipped with a Zeiss AxioCam MRm camera (Carl Zeiss MicroImaging GmbH, Germany). For each
292 tissue slice, images were captured with a 10x objective and stitched into a single composite image
293 using Zen Blue Edition software (Carl Zeiss MicroImaging GmbH, Germany). Relative Optical Density
294 (ROD) analysis was performed on 8-bit converted images using ImageJ software (National Institutes of
295 Health, USA) to quantify the mean fluorescence of dopaminergic fibers in the striatum, based on a
296 calibration curve. Quantification of TH-positive neurons in the substantia nigra was conducted using
297 NeuroLucida software (MBF Bioscience).

298 *Cortical vesicular markers analysis:* High-magnification z-stack images (5 stacks, z-step 0.17 µm) of
299 cortical vesicular markers for excitatory (VGLUT1 and VGLUT3) and inhibitory (VGAT) neurons were
300 acquired using a Zeiss Airyscan Confocal Microscope (Carl Zeiss MicroImaging GmbH, Germany),
301 equipped with a 63× oil objective and a 1.3 digital zoom. The images were processed and converted in
302 8-bit images with ImageJ software to analyze the mean fluorescence of synaptic marker puncta-ring
303 regions surrounding the cell body, subtracting the mean fluorescence of the cell body as background.
304 Similarly, the mean fluorescence of PV puncta surrounding non-PV cell bodies was analyzed to assess
305 the synaptic activity of PV-INs in cortical areas that were identified through wide-field imaging as
306 hypoconnected in the 6-OHDA mouse model. For each hemisphere, a minimum of three cells were
307 analyzed across three fields of view from three brain sections per animal, resulting in a total of n=216
308 cells per cortical marker. The mean values for the ipsilateral hemisphere were then normalized to the
309 corresponding contralateral hemisphere, which served as the internal control.

310 *PV-IN density and distribution:* The density and distribution of PV⁺ cell bodies were analyzed across
311 three cortical regions: M1, M2, and S1BF. PV-IN cell bodies signals were acquired using a Zeiss Axio
312 Observer microscope equipped with a Zeiss AxioCam MRm camera (Carl Zeiss MicroImaging GmbH,

313 Germany). For each region, the entire cortical thickness was subdivided into five equal bins, with Bin 1
314 representing the most superficial layer and Bin 5 the deepest. In M2, due to anatomical constraints,
315 only the three most superficial bins (Bins 1-3) were analyzed. The number of PV-IN cell bodies within
316 each bin was quantified and expressed as the density of cells per square millimeter (cells/mm²). This
317 allowed for a precise assessment of PV-IN distribution across cortical depths within each brain region.
318 *PV-IN morphology*: PV-IN morphology was analyzed ex vivo in the motor cortex of PV-Cre mice injected
319 with the Cre-dependent AAV-PHP.eB/2-hSyn1-chl-dlox-jGCaMPf(rev)-dlox-WPRE-SV40p(A) virus,
320 following wide-field imaging. The robust GFP signal expressed by the virus enabled the detailed
321 visualization and analysis of small dendrites and all neurons co-localizing with PV⁺ cells. Confocal z-
322 stacks spanning approximately 40 μm were acquired with a z-step of 0.23 μm , resulting in a final voxel
323 size of 0.31 \times 0.31 \times 0.23 μm . Images were subsequently processed using the Filament Tracer Tool of
324 IMARIS software (Bitplane) for semi-automatic three-dimensional reconstruction and quantitative
325 morphometric analysis. For each hemisphere and analyzed mouse, approximately 10 PV⁺ cortical
326 neurons per animal were reconstructed, allowing for a detailed assessment of dendritic architecture and
327 cellular morphology.

328 *Microglia analysis*: for microglial density analysis, 1024x1024 pixel images were acquired with a
329 confocal microscope (Stellaris 8 confocal microscope, Leica microsystems) using an 20x objective (HC
330 PL APO CS2, 20x/0.75 DRY), and pinhole was set to 1 AU. Sequential illumination with 488 nm laser
331 lines was used to detect Iba1. The central plane of the sample in the z-axis was selected for image
332 acquisition. Images were processed through Fiji Image software: microglia somata and areas of brain
333 regions (in μm) were counted by combining the Cell Counter and selection of ROI options. Density was
334 calculated as the number of soma divided by the area, and expressed as n of cells/mm².

335

336 **Statistical Analysis**

337 Statistical analyses were performed using Prism software (GraphPad, USA). All values reported are the
338 mean \pm SEM (indicated in the caption). For all analyses, $\alpha = 0.05$. To determine the employment of
339 statistical parametric or non-parametric tests, a normality test has been performed (Shapiro-Wilk test
340 or Kolmogorov-Smirnov test). For behavioral test analysis a two-way repeated measures ANOVA
341 followed by Sidak's multiple comparisons test was used to compare 6-OHDA vs CNT and for
342 longitudinal intragroup studies. For histological analyzes a two-way repeated measures ANOVA
343 followed by Sidak's multiple comparisons test was used to compare CNT contra, CNT ipsi, 6-OHDA
344 ipsi, 6-OHDA contra.

345

346 **PCA Analysis**

347 PCA analysis was performed on python (sklearn.decomposition.PCA) using as a dataset all the
348 collected parameters for each animal (9 animals, 49 features including histology and functional
349 connectivity data). Each feature's loading in PC1 was assessed by looking at `pca.components_` and
350 ranked.

351 *Training of the SVM classifier*: To identify potential biomarkers for classifying mice as diseased(6-
352 OHDA) or non-diseased (CNT) , we implemented a Support Vector Machine (SVM) classification
353 approach using a leave-one-out cross-validation (LOOCV) strategy. The dataset used was the same
354 as for *PCA Analysis*. Prior to classification, the features were standardized using
355 `sklearn.preprocessing.StandardScaler` to ensure comparability and optimal performance of the SVM.
356 To rigorously evaluate model performance and ensure unbiased estimation of classification accuracy
357 given the low number of rows, we used LOOCV. In this approach, each mouse sample was sequentially
358 left out as the test set while the remaining samples were used to train the SVM model. This process
359 was repeated until every sample had been used once as the test set. The SVM classifier was thus
360 trained using either the entire dataset (All), only histological parameters for puncta markers (Puncta),
361 only histological parameters for lesion quantification - CPU Th⁺ fibers and SNc Th⁺ neurons - (Lesion),
362 only functional connectivity data (FC). To validate the accuracy of the classification model, we
363 generated a scrambled version of the dataset by randomly shuffling the class labels while keeping the

364 feature data intact. The same LOOCV procedure was applied to this scrambled dataset to establish a
365 baseline for comparison (bootstrap).

366

367 RESULTS

368

369 *Disrupted Cortical and Striatal Circuit in the 6-OHDA Mice*

370 To induce a slow and stable loss of dopaminergic neurons and model Parkinson's Disease (PD), we
371 unilaterally injected 6-hydroxydopamine (6-OHDA) into the striatum of adult mice, while control mice
372 (CNT) underwent sham surgery with vehicle injection. For histological evaluation, tyrosine hydroxylase-
373 positive (TH⁺) immunohistochemistry in substantia nigra pars compacta (SNc) was performed
374 (Supplementary Fig. 1a, b). In line with previous evidence [14], a pronounced loss of TH⁺ neurons was
375 observed in SNc of the injured hemisphere, along with a marked reduction in TH⁺ fibers in the caudate-
376 putamen (CPu) (Supplementary Fig. 1c, d). We then evaluated motor deficits by using the Cylinder
377 Test. Our results confirmed a pronounced asymmetry in forelimbs use in 6-OHDA-lesioned mice,
378 characterized by a reduced use of the paw contralateral to the injection without any recovery over time
379 (Supplementary Fig. 1e, f).

380 In order to evaluate how dopaminergic loss alters local oscillatory activity and synchronization between
381 the striatum and motor cortex, a chronic implant was placed for simultaneous electrophysiological
382 recordings from both regions following 6-OHDA stereotaxic injection. Local field potentials (LFPs) were
383 recorded weekly from awake, head-restrained mice in resting-state condition (Fig. 1a), when no forelimb
384 movement was detected by the load cell.

385 The LFP of both groups displayed prominent delta oscillations, with a characteristic peak around 4 Hz,
386 in both the striatum (Fig. 1b) and motor cortex (Supplementary Fig. 2a). In the striatum, the power of
387 delta oscillations was modulated by both the recording stage and the experimental group. Over time, 6-
388 OHDA mice demonstrated a clear trend of increasing delta power (Fig. 1c). By the final recording stage,
389 delta power in 6-OHDA mice was significantly higher compared to controls. This progressive increase
390 suggests a temporal evolution of striatal oscillatory activity in 6-OHDA mice. In the motor cortex, delta
391 oscillations in 6-OHDA mice followed a similar upward trend across recording stages (Supplementary
392 Fig. 2a). However, unlike in the striatum, this increase did not reach statistical significance when
393 compared to the corresponding oscillations in controls (Supplementary Fig. 2b).

394 Across both the striatum and motor cortex, power in other frequency bands, including beta and gamma,
395 did not exhibit clear temporal trends or significant differences between the two groups (Supplementary
396 Fig. 2c-f).

397 Next, we examined the relationship between the spectral features of LFPs in the striatum and motor
398 cortex across the two experimental groups (Fig. 1d). To evaluate spectral connectivity between these
399 regions, we computed spectral coherence (see Materials and Methods). Both groups exhibited
400 significant delta-band coherence between the striatum and motor cortex during the resting state (Fig.
401 1e), with coherence being significantly influenced by the recording stage. In the 6-OHDA group, delta
402 coherence progressively and consistently increased over recording stages (Fig. 1e), culminating in a
403 statistically significant difference from controls during the later recording stages.

404 To further explore this enhanced coupling, we computed the cross-correlation between the temporal
405 dynamics of striatal and cortical delta power (Fig. 1f). Consistent with the coherence findings, cross-
406 correlation peaks demonstrated significant modulation across experimental groups and a significant
407 interaction effect between group and recording week. In 6-OHDA-treated mice, cross-correlation of
408 delta power between the striatum and motor cortex progressively increased over time, becoming
409 significantly elevated compared to control mice as early as the intermediate stage post-toxin injection.
410 These findings indicate that the neurodegenerative processes induced by 6-OHDA injection enhance
411 the synchronization of delta oscillations between the striatum and motor cortex.

412 Finally, we investigated the time lag at which the maximum cross-correlation occurred between striatal
413 and cortical delta power. No significant differences in the optimal time lag were observed between
414 groups or across recording weeks (Fig. 1g). This suggests the absence of a direct causal relationship
415 in the temporal evolution of delta power between the striatum and motor cortex.

416

417 ***Voluntary movement induced increased high-gamma spectral modulation in 6-OHDA mice***
418 ***motor cortex***

419 Next, to identify specific alterations in motor function-related activity in the striatum and motor cortex,
420 we investigated the spectral modulation induced by voluntary movement in both control (n=6) and 6-
421 OHDA (n=7) mice. To this end, LFPs were simultaneously recorded from the cortex and striatum as the
422 mice performed a voluntary forelimb retraction task using the M-Platform, a custom-designed apparatus
423 for functional evaluation and neurorehabilitation of forelimb movement in mice [17, 19, 27].

424 The LFP recordings were segmented into time windows spanning from [-1500 ms to +500 ms] relative
425 to movement onset, which was identified using a custom detection algorithm (see Materials and
426 Methods). Time-frequency scalograms were computed for each segment and normalized to a baseline
427 period, defined as the average scalogram from [-1500 ms to -750 ms], with no force peak detected (Fig.
428 1h).


429 In control mice, voluntary movement elicited robust spectral modulation in the striatum, spanning a
430 broad frequency range during the early recording stage (Fig. 1i, top-left). However, this modulation
431 diminished progressively over time, and by the late recording weeks, little to no movement-related
432 spectral activity was observed (Fig. 1i, top-right). In contrast, 6-OHDA mice exhibited minimal
433 movement-induced spectral modulation in the striatum already from the early recording stage, with the
434 only exceptions of delta and high-gamma (Fig. 1i, bottom row). Accordingly, striatal delta power
435 modulation exhibited a decreasing trend in both control and 6-OHDA mice (Fig. 1k), though the
436 reduction was more pronounced in 6-OHDA mice. By the late recording stage, 6-OHDA mice showed
437 a complete loss of delta modulation, which led to a statistically significant difference between the two
438 groups during this phase. Similarly, striatal high-gamma modulation declined progressively in control
439 mice across recording weeks (Fig. 1l). Interestingly, this pattern was not observed in 6-OHDA mice,
440 where high-gamma modulation in the early stage of recording was comparable to the levels seen in
441 control mice at the end of the recording period (Fig. 1l).

442 A similar progressive reduction in spectral modulation was observed in cortical LFPs of control mice
443 (Fig. 1j, top row). During the initial weeks of recording, voluntary movements elicited increases in power
444 across multiple frequency bands, particularly in the delta, beta, and high-gamma ranges (Fig. 1j, top-
445 left). However, this movement-induced spectral modulation diminished steadily over the course of the
446 recording weeks. In 6-OHDA mice, a similar pattern of movement-induced spectral modulation was
447 observed during the early recording stage (Fig. 1j, bottom-left), with increases in delta, beta, and high-
448 gamma power. Over time, however, spectral modulation in these mice decreased in a manner that
449 paralleled the trend seen in controls, except in the high-gamma range, where an opposing trajectory
450 emerged. Specifically, delta power modulation in the cortex followed a similar declining trajectory in
451 both control and 6-OHDA mice, with a gradual reduction over recording weeks (Fig. 1n). In contrast,
452 high-gamma power modulation displayed divergent trends between the two groups (Fig. 1o). High-
453 gamma progressively decreased in control mice over the recording weeks, while it increased steadily
454 in 6-OHDA mice. By the late stages of recording, this divergence resulted in a statistically significant
455 difference in high-gamma modulation between the two groups (Fig. 1o).

456 Although significant changes in cortical high-gamma power modulation were observed, these changes
457 did not translate into alterations in mean force output across the recording stages (Fig. 1m). The mean
458 force remained stable in both control and 6-OHDA-treated mice, with no significant differences between
459 the groups. However, the area under the force curve (AUC) increased significantly in 6-OHDA-treated
460 mice during the late stage (Fig. 1p). This increase likely indicates a reduction in the precision of
461 movement, resulting in a more dispersed force profile over time. While the mean force output remains
462 unchanged, its distribution appears less focused, suggesting an alteration in movement control in 6-
463 OHDA-treated mice.

464 Finally, to further investigate the potential implications of cortical high-gamma modulation in 6-OHDA-
465 treated mice, we assessed its correlation with behavioral and cellular markers (Supplementary Fig. 2g).
466 A significant negative correlation was observed between cortical high-gamma power and performance
467 in the behavioral test at 28 days post-lesion (Supplementary Fig. 2h), indicating that increased cortical

468 high-gamma activity might be associated with motor performance deficits. Additionally, cortical high-
 469 gamma power was inversely correlated with the number of TH⁺ cells in SNc (Supplementary Fig. 2i),
 470 as well as the intensity of TH⁺ fibres in striatum (Supplementary Fig. 2j), indicating a link between
 471 increased cortical high-gamma activity and dopaminergic degeneration. These findings suggest that
 472 the pathological increase in cortical high-gamma activity may be the effect of circuit rearrangements in
 473 response to progressive nigrostriatal degeneration. Together, these correlations provide a link between
 474 cortical spectral changes, cellular degeneration, and motor impairments, highlighting the complex
 475 interplay between neurophysiological, behavioral, and cellular adaptations in the 6-OHDA Parkinsonian
 476 model.
 477



478


479 Fig 1. LFPs during resting state revealed increased striatal delta power and striatum-cortical coherence in 6-OHDA-treated mice.
480 **a** The experimental protocol involved unilateral stereotaxic injection of 6-OHDA into the striatum to establish a PD mouse model
481 (in orange n=13), with a control group receiving vehicle injections (in blue n=8). LFPs were simultaneously recorded from the
482 striatum and motor cortex on a weekly basis, during both spontaneous resting states and motor task performance. Recording
483 weeks were grouped into three stages: early (recording week =1); intermediate ($2 \leq \text{recording week} \leq 3$); late (recording week =4).
484 **b** Average power spectral density of LFPs in the striatum of control (in blue, CNT n=8) and 6-OHDA mice (in orange, 6-OHDA
485 n=13) across recording stages. Zoomed inset provides focus on the low-frequencies part of the PSD. **c** Spectral power of striatal
486 delta oscillations across recording weeks in controls (in blue, CNT n=8) and 6-OHDA mice (in orange, 6-OHDA n=13). Two-way
487 ANOVA $F_{\text{Stages} \times \text{Groups}} = 2.46$ $p=0.08$, $F_{\text{Stages}} = 10.2$ $p=0.0001$, $F_{\text{Groups}} = 8.51$ $p=0.004$; 6-OHDA vs CNT late stage $p=0.0001$ Wilcoxon
488 rank-sum test with Holm–Bonferroni correction. **d** Spectral coherence between striatal and cortical LFPs of (in blue, CNT n=8)
489 and 6-OHDA mice (in orange, 6-OHDA n=13) across recording stages. Zoomed inset provides focus on the low-frequencies part
490 of the PSD. **e** Coherence within the delta range in controls (in blue, CNT n=8) and 6-OHDA mice (in orange, 6-OHDA n=13)
491 across recording stages. Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 2.01$ $p=0.13$, $F_{\text{Stages}} = 3.82$ $p=0.02$, $F_{\text{Groups}} = 2.32$ $p=0.10$. 6-OHDA vs
492 CNT late stage $p=0.02$ Wilcoxon rank-sum test with Holm–Bonferroni correction. **f** Maximal cross-correlation across recording
493 stages of the dynamics of delta power in control (in blue, CNT n=8) and 6-OHDA mice (in orange, 6-OHDA n=13). Two-way
494 ANOVA $F_{\text{Stages} \times \text{Groups}} = 3.88$ $p=0.02$, $F_{\text{Stages}} = 1.9$ $p=0.15$, $F_{\text{Groups}} = 11.11$ $p=0.001$. 6-OHDA vs CNT intermediate stage $p=0.004$, 6-
495 OHDA vs CNT late stage $p=0.02$ Wilcoxon rank-sum test with Holm–Bonferroni correction. **g** Optimal time lag for cross-correlation
496 across recording stages of the dynamics of delta power in control (in blue, CNT n=8) and 6-OHDA mice (in orange, 6-OHDA
497 n=13). Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 0.14$ $p=0.87$, $F_{\text{Stages}} = 0.2$ $p=0.82$, $F_{\text{Groups}} = 1.37$ $p=0.24$. **h** Windows of analysis during the
498 task in relation to movement onset. The black line represents an example of force trace throughout the task; the onset of the
499 movement is highlighted; the orange window identifies the baseline period when no movement is detected; the pink window
500 identifies the pre-onset phase (i.e. movement preparation) and the green window the post-onset phase (i.e. movement). **i-j**
501 Average modulation of striatal **i** and cortical **j** LFPs time-frequency scalogram centered around movement onsets (vertical dashed
502 white line) normalized by a baseline ([-1500,-750] ms before movement onsets) across recording stages (indicated in the panels'
503 titles) in controls (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-OHDA n=7). **k** Modulation of delta power in striatal LFPs
504 around movement onsets (0-250 ms) across recording stages in control (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-
505 OHDA n=7). Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 0.74$ $p=0.48$, $F_{\text{Stages}} = 4.29$ $p=0.01$, $F_{\text{Groups}} = 6.14$ $p=0.01$. 6-OHDA vs CNT late stage
506 $p=0.0033$ Wilcoxon rank-sum test with Holm–Bonferroni correction. **l** Modulation of high gamma power in striatal LFPs around
507 movement onsets (0-250 ms) across recording stages in control (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-OHDA n=7).
508 Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 5.02$ $p=0.007$, $F_{\text{Stages}} = 15.4$ $p<0.0001$, $F_{\text{Groups}} = 12.31$ $p=0.0005$. 6-OHDA vs CNT early stage
509 $p=0.0042$ Wilcoxon rank-sum test with Holm–Bonferroni correction. **m** Variation of mean force exerted detected from the robotic
510 M-platform in control (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-OHDA n=7). Repeated Two-way ANOVA Sidak's multiple
511 comparisons test was used. **n** Cortical delta power modulation in control (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-
512 OHDA n=7): Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 0.76$ $p=0.46$, $F_{\text{Stages}} = 8.54$ $p=0.0002$, $F_{\text{Groups}} = 1.01$ $p=0.31$. **o** Cortical high-gamma
513 power modulation in control (in blue, CNT n=6) and 6-OHDA mice (in orange, 6-OHDA n=7): Two-way ANOVA $F_{\text{Stages} \times \text{Groups}} = 6.68$
514 $p=0.001$, $F_{\text{Stages}} = 3.17$ $p=0.04$, $F_{\text{Groups}} = 3.99$ $p=0.04$. 6-OHDA vs CNT late stage $p=0.001$ Wilcoxon rank-sum test with Holm–
515 Bonferroni correction. **p** Variation of area under the force curve detected from the robotic M-platform in control (in blue, CNT n=6)
516 and 6-OHDA mice (in orange, 6-OHDA n=7). Repeated Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Stages} \times \text{Groups}} (2,$
517 $33) = 4.88$ $p=0.014$, $F_{\text{Stages}} (2, 33) = 6.83$ $p=0.0033$, 6-OHDA vs CNT late stage $p=0.037$. Mean \pm SEM. * $p \leq 0.05$; ** $p < 0.01$;
518 *** $p < 0.001$; **** $p < 0.0001$. See also Supplementary Figures 1, 2 and Supplementary Table 1.

519 **Dopaminergic neuron loss impact PV-INs functional cortical network**

520 Electrophysiological results suggest that dopaminergic degeneration may affect broader cortical
521 network connectivity. Specifically, increased high-gamma modulation in the motor cortex of 6-OHDA
522 mice pointed to a compensatory or maladaptive change in neuronal dynamics mediated by
523 parvalbumin-positive interneurons (PV-INs) [10, 28, 29]. Therefore, we used wide-field (WF) calcium
524 imaging to longitudinally investigate how functional cortical connectivity of PV-INs changed from 14 to
525 28 days post lesion in 6-OHDA mice.

526 PV-Cre mice were administered retro-orbital injection with a PHP.eB serotype AAV expressing
527 GCaMP7f under the parvalbumin (PV) promoter in a Cre-dependent manner. After two weeks, unilateral
528 stereotaxic injection of 6-OHDA into the striatum was performed to generate the PD mouse model (6-
529 OHDA), with a control group receiving a vehicle injection (CNT). Then, weekly WF imaging and Schallert
530 Cylinder test were conducted starting from 14 days post lesion (DPL) for three weeks (Fig. 2a). The
531 efficiency and specificity of viral infection were validated by post-mortem immunohistological inspection,
532 showing that 90% of PV⁺ neurons were successfully transfected with the GCaMP, and 78% of GCaMP⁺
533 neurons were effectively identified as PV⁺ neurons (Supplementary Fig. 3a, b). These findings confirm
534 that PHP.eB transfection achieved both high efficacy and target specificity. Moreover, motor deficits in
535 the use of the contralateral forelimb (Supplementary Fig. 3c), dopaminergic neuron loss in both SNc
536

537 (Supplementary Fig. 3d) and CPu (Supplementary Fig. 3e) were validated, exhibiting a similar trend to
538 that observed in the electrophysiological group (Supplementary Fig. 3d-f).
539 In vivo imaging sessions were performed in awake, head-fixed mice at 14, 21 and 28 DPL for both CNT
540 (n=6) and 6-OHDA (n=5) groups (Fig. 2c). Hemoglobin signal was removed from the calcium data, and
541 global signal regression was applied to eliminate global signal contributions. Resting-state functional
542 connectivity (rs-FC) was assessed by defining a set of 22 regions of interest (ROIs) covering both the
543 hemispheres (Fig. 2b). Correlation matrices were computed for each group using pairwise Pearson
544 correlation (Fig. 2d). Differences in rs-FC between CNT and 6-OHDA groups were then quantified by
545 comparing the average correlation matrices of injured mice to those of healthy controls at each time
546 point (Fig. 2e). Results revealed abnormalities in the PV-INs cortical functional network, showing both
547 hypo- and hyper-connectivity patterns in 6-OHDA mice, which appeared to gradually intensify over time
548 (Fig. 2e). Using the network-based statistic (NBS) we therefore tested for significant changes in FC.
549 Relative to the control group, 6-OHDA mice exhibited pronounced hyper-connectivity of the
550 somatosensory areas. Decreased connectivity was instead observed bilaterally in the barrelfield cortex
551 and predominantly in the primary motor cortex of the ipsilateral hemisphere to the lesion (Fig. 2f). Our
552 results showed the emergence of a significantly altered network at 28 DPL, characterized by concurrent
553 patterns of hypo- and hyper-connectivity across brain regions.
554 To identify the features contributing most to the network alterations, we studied FC dynamics globally
555 and then we further categorized FC into inter-hemispheric or intra-hemispheric connections
556 (Supplementary Fig. 3f). The 6-OHDA group consistently exhibited higher global FC values compared
557 to the control group across all time points (Fig. 2g), suggesting a possible hypersynchronization of the
558 circuitry. These differences increased over time, despite the control group remaining stable throughout,
559 by reflecting an early and acute response to the dopaminergic neuron loss. Interestingly, intra-
560 hemispheric connectivity both contralateral and ipsilateral to the lesion did not show any significant
561 variation over time by highlighting that functional connections within a single hemisphere were more
562 stable and less affected by the lesion (Supplementary Fig. 3g, h). In contrast, transcallosal
563 communications were significantly disrupted among cortical regions in 6-OHDA mice by contributing
564 substantially to the network alterations over all time points investigated (Fig. 2h).
565 To further evaluate FC alterations potentially related to motor or sensory deficits, we then focused on
566 three main regions of interest: the secondary and primary motor cortex, critical for movement regulation,
567 and the barrelfield cortex, a key area for sensory processing in mice. The secondary motor cortex (MOs-
568 p) showed stable FC over time in both contralateral- and ipsilateral hemisphere (Fig. 2i, j) by suggesting
569 that this cortical region remains relatively resilient to dopaminergic neuron loss. A similar trend was
570 observed also in the primary motor cortex of the contralateral hemisphere (Fig. 2k). In contrast, FC was
571 significantly reduced as early as 21 DPL in the primary motor cortex of the ipsilateral hemisphere (Fig.
572 2l) indicating an early onset of alterations on motor regions. Barrel field cortex instead exhibited a trend
573 toward hypoconnectivity in the 6-OHDA group with more pronounced effects in the contralateral
574 hemisphere compared to the ipsilateral one (Fig. 2m, n).
575 Taken together, these results suggest that while the pathological phenotype remains consistent over
576 time, with an immediate and stable impairment, FC shows a progressive deterioration with emergence
577 of an altered network at 28 DPL. Notably, dopaminergic loss affects primarily inter-hemispheric
578 connections by suggesting a stronger impact on the coordination between the two hemispheres.



579
580
581
582
583
584
585
586
587
588
589
590
591
592

Fig. 2 Altered network of PV-INs rs-FC in 6-OHDA mouse model. **a** Experimental timeline for PV-INs longitudinal WF calcium imaging. **b** Representative image of the WF field-of-view. Colored squares represent the cortical parcellation ROI map based on the Allen Brain Atlas. White dots indicate Bregma (top) and Lambda (bottom). Scale bar = 1 mm. **c** Representative sequences of cortical activity in resting state condition (RS) at 14 days post-lesion (14 DPL), 21 and 28 DPL in control (CNT, top) and 6-OHDA treated group (bottom). **d** Dynamics of the averaged functional connectivity PV network (Pearson's correlation) over the days (14, 21 and 28 DPL) for the control group (CNT $n=4$, bottom right) and 6-OHDA-treated group (6-OHDA $n=5$, top left). **e** Matrix of difference displaying average FC differences between CNT and 6-OHDA over the days, calculated by subtracting the averaged FC of the CNT group from that of the 6-OHDA group. Red squares represent regions of 6-OHDA hyperconnectivity, while blue squares denote 6-OHDA hypoconnectivity. **f** Network diagram of statistically significant FC alterations at 28 DPL (left). Red and blue lines represent significant hyper- and hypo-correlations of the 6-OHDA group compared with the CNT group, respectively. The bar plot (right) shows the number of significant FC (hypo left, hyper right) related to each cortical area ($p < 0.05$, NBS, $n=4$ CNT and 5 6-OHDA). **g** Box plot showing the mean global signal PV-FC in the CNT group (light blue) compared to the 6-OHDA group (orange) at 14, 21 and 28 DPL. Repeated Two-way ANOVA with Sidak's multiple comparisons test ($F_{Groups} (1, 7) = 19.12$

593 p=0.003; 6-OHDA vs CNT 14DPL p=0.014; 21DPL p=0.024; 28DPL p=0.0004). **h** Box plot showing the mean inter-hemispheric
594 PV-FC in the CNT group (light blue) compared to the 6-OHDA group (orange) at 14, 21 and 28 DPL. Repeated Two-way ANOVA
595 with 6-OHDA vs CNT ($F_{\text{Groups}}(1, 7) = 19.49$ p=0.0031; 6-OHDA vs CNT 14DPL p=0.0250; 21DPL p=0.0094; 28DPL p=0.0005). **i-j**
596 Box plots show comparison of the PV-FC for the posterior area of the secondary motor cortex between CNT and 6-OHDA group
597 (light blue and orange, respectively) at 14, 21 and 28 DPL in the left hemisphere (I, Repeated Two-way ANOVA) and right
598 hemisphere (J, Repeated Two-way ANOVA). **k-l** Box plots show comparison of the PV-FC for the anterior area of the primary
599 motor cortex between CNT and 6-OHDA group (light blue and orange, respectively) at 14, 21 and 28 DPL in the left hemisphere
600 (K,) and right hemisphere (L, Repeated Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups}}(1, 7) = 13.66$ p=0.007;
601 6-OHDA vs CNT 21DPL p=0.028; 28DPL p=0.033). **m-n** Box plots show comparison of the PV-FC for the barrelfield cortex
602 between CNT and 6-OHDA group (light blue and orange, respectively) at 14, 21 and 28 DPL in the left hemisphere (M, Repeated
603 Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups}}(1, 7) = 8.81$ p=0.021; 6-OHDA vs CNT 21DPL p=0.028; 28DPL
604 p=0.0040) and right hemisphere (N, Repeated Two-way with Sidak's multiple comparisons test $F_{\text{Time}}(2, 14) = 4.71$ p=0.027,
605 $F_{\text{Groups}}(1, 7) = 7.15$ p=0.032; 6-OHDA vs CNT 28DPL p=0.049). In blue, CNT n=5 and in orange, 6-OHDA n=4. Mean \pm SEM.
606 *p<0.05; **p<0.01; ***p<0.001. See also Supplementary Figure 3 and Supplementary Table 2.

607

608 **Synaptic Puncta Output Compensates for PV-INs Deficiency in the Hypoconnected Areas**

609 In the 6-OHDA mouse model, motor and sensory cortical areas exhibit disrupted functional connectivity
610 of PV-IN networks. PV-INs play a critical role in synchronizing activity across cortical regions and
611 generating gamma oscillations, which are essential for proper cortical processing. This dysfunction may
612 underlie motor and cognitive deficits associated with Parkinson's disease [30].

613 Given their role in cortical synchrony and interhemispheric coordination, we investigated potential
614 alterations in PV-IN density, distribution, and synaptic connectivity. By analyzing PV+ neurons and the
615 surrounding puncta rings on non-PV neuronal somata in superficial layers II/III (Fig. 3a), we identified
616 changes in the inhibitory network associated with dopaminergic loss.


617 The density of cortical PV-INs showed a significant decrease in the 6-OHDA group compared to
618 controls. This reduction was consistent across all cortical regions investigated, including M2 (Fig. 3b),
619 M1 (Fig. 3c), and S1BF (Fig. 3d). In M2, only the three most superficial cortical bins were analyzed due
620 to anatomical constraints, yet the results mirrored those seen in the other regions. These observations
621 align with earlier findings from wide-field imaging, suggesting that PV-IN loss is associated with
622 disrupted cortical networks.

623 The reduction in PV-IN density exhibited a symmetric distribution between hemispheres and consistent
624 uniformity across cortical layers. Interestingly, quantitative analysis of presynaptic puncta-rings
625 encircling non-PV neurons (Fig. 3e) revealed significant differences between experimental groups.
626 Across all the three cortical areas investigated, a marked reduction in puncta-ring intensity around non-
627 PV neuronal somata was observed in the contralateral hemispheres of 6-OHDA mice (Fig. 3f-h).
628 Conversely, the ipsilateral hemisphere of 6-OHDA mice showed no significant differences compared to
629 the control and, in M1, presynaptic puncta-ring density even appeared to be higher (Fig. 3f-h).
630 These results revealed a discrepancy: despite the loss of PV-INs, inhibitory synaptic contacts did not
631 appear to decrease proportionally. To further investigate this hypothesis, we analyzed the relationship
632 between PV-IN reduction and puncta-ring density by normalizing PV puncta density to PV-IN density.
633 In M2 (Fig. 3i), there was a symmetric increase in the PV puncta density/PV-IN density ratio for 6-OHDA
634 mice by suggesting a heavy compensatory mechanism in both the hemispheres. In M1 (Fig. 3j), the
635 ipsilateral hemisphere of 6-OHDA mice exhibited the most significant increase in the ratio. In contrast,
636 contralateral hemisphere values remained consistent with control levels, by suggesting a lack of
637 compensatory upregulation. In S1BF of 6-OHDA mice (Fig. 3k) instead there was a trend toward a
638 higher ratio in the ipsilateral hemisphere. However, this compensation appears less pronounced
639 compared to the motor regions.

640 Our results suggest that, despite the symmetric loss of PV-INs, their synaptic output is selectively
641 upregulated in the ipsilateral hemisphere. This mismatch indicates the presence of a compensatory
642 mechanism, potentially involving an increase in the strength of synaptic contacts formed by the long-
643 range PV-INs to counterbalance the loss of inhibitory neurons.

644 To assess morphological complexity of PV-IN, we performed 3D dendritic reconstructions (Fig. 3l) and
645 3D Sholl analysis (Fig. 3m), revealing a significant reduction in total branching points in the ipsilateral
646 hemisphere of 6-OHDA-lesioned mice compared to the contralateral side (Fig. 3n). These findings
647 suggest that dopamine depletion may induce dendritic atrophy in PV-INs, potentially disrupting local

648 circuit organization, impairing their ability to maintain inhibitory network stability and recruiting long-
 649 range connections.
 650



651
 652 Fig. 3 Parvalbumin-positive interneurons (PV-INs) cortical layers' distribution, density and PV ring point in the cortex. **a** Cortical
 653 PV-IN density and layer distribution. Representative coronal section representing the regions of interest. Scale bar: 1 mm. The
 654 cortical distribution of PV-INs across five homogenous bins spanning the entire cortical thickness in **b** secondary motor cortex
 655 (M2, Two-way ANOVA $F_{Groups} (3, 42) = 30.14$ $p < 0.0001$, $F_{Bins} (2, 42) = 28.40$ $p < 0.0001$), **c** primary motor cortex (M1, Two-way
 656 ANOVA $F_{Groups \times Bins} (12, 70) = 2.24$ $p = 0.019$, $F_{Groups} (3, 70) = 48.09$ $p < 0.0001$, $F_{Bins} (4, 70) = 69.29$ $p < 0.0001$) and **d** primary
 657 somatosensory barrel cortex (S1BF, Two-way ANOVA $F_{Groups} (3, 70) = 8.91$ $p < 0.0001$, $F_{Bins} (4, 70) = 66.86$ $p < 0.0001$). In particular,
 658 in M2 only the 3 more superficial bins have been analyzed due to anatomical regions. Specific statistical values are reported in
 659 supp table 5. **e** High magnification of the cortex immunostained with anti-PV for CNT and 6-OHDA groups. Interhemispheric

660 analysis of anti-PV fluorescence mean values of puncta-rings, calculated in puncta-rings around cell bodies of non-PV positive
661 neurons in control and 6-OHDA group. Data from three fields of view per three brain sections n=72 cells for each dataset and
662 CNT animals n=6 vs 6-OHDA animals n=5 were analysed. **f** In M2 interhemispheric analysis of anti-PV fluorescence mean values
663 of puncta-rings in control and 6-OHDA group. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Hemisphere}}(1, 14) = 5.28$
664 $p=0.038$; contra vs ipsi 6-OHDA $p=0.036$. **g** In M1. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups} \times \text{Hemisphere}}(1,$
665 $14) = 14.80$ $p=0.0018$, $F_{\text{Hemisphere}}(1, 14) = 11.92$ $p=0.0039$; contra vs ipsi 6-OHDA $p=0.0005$; 6-OHDA vs CNT contra $p=0.011$. **h**
666 In S1BF. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups} \times \text{Hemisphere}}(1, 14) = 4.92$ $p=0.044$, $F_{\text{Groups}}(1, 14) = 6.18$
667 $p=0.026$, $F_{\text{Hemisphere}}(1, 14) = 7.45$ $p=0.016$; contra vs ipsi 6-OHDA $p=0.010$. 6-OHDA vs CNT contra $p=0.010$. **i-k** Normalized PV
668 puncta density (PV puncta per PV-IN) in superficial layers of the ipsilateral and contralateral hemispheres across cortical regions
669 in the controls (in blue) and 6-OHDA (in orange) group. **i** In M2. Two-way ANOVA with Sidak's multiple comparisons test F_{Groups}
670 $(1, 14) = 12.79$ $p=0.0030$; 6-OHDA vs CNT contra $p=0.030$. **(j)** In M1. Two-way ANOVA with Sidak's multiple comparisons test
671 $F_{\text{Groups} \times \text{Hemisphere}}(1, 14) = 7.93$ $p=0.014$, $F_{\text{Groups}}(1, 14) = 17.58$ $p=0.0009$, $F_{\text{Hemisphere}}(1, 14) = 9.68$ $p=0.0077$; contra vs ipsi 6-OHDA
672 $p=0.0028$; 6-OHDA vs CNT contra $p=0.0004$. **k** In S1BF. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups} \times \text{Hemisphere}}$
673 $(1, 14) = 2.08$ $p=0.17$. In blue, CNT n=5 and in orange, 6-OHDA n=4. **l** IMARIS semi-automatic three-dimensional reconstruction
674 and quantitative morphometric analysis of PV-IN. Scale bar, 20 μm . **m** Sholl analysis to study PV-IN morphology complexity in
675 M1. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Radius}}(139, 1820) = 199.2$ $p<0.0001$, $F_{\text{Group}}(3, 1820) = 36.83$
676 $p<0.0001$. **n** Interhemispheric analysis of PV-IN total branching points in control and 6-OHDA mice in M1. Two-way ANOVA with
677 Sidak's multiple comparisons test $F_{\text{Groups} \times \text{Hemisphere}}(1, 14) = 11.82$ $p=0.0040$, $F_{\text{Hemisphere}}(1, 14) = 11.45$ $p=0.0045$; contra vs ipsi 6-
678 OHDA $***p=0.0009$; CNT vs 6-OHDA ipsi $*p=0.032$. In blue, CNT n=5 and in orange, 6-OHDA n=4. Mean \pm SEM. $*p \leq 0.05$;
679 $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$. See also Supplementary Table 3 and 4.

680

681

PV-INs Functional Connectivity Predicts Pathology Progression

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705


706

707

708

709

We then aimed to assess the potential of FC as a biomarker for disease progression in the 6-OHDA model of PD. To achieve this, we first integrated the entire dataset, encompassing both physiological and histological data, and performed principal component analysis (PCA) to determine whether the two groups could be distinctly separated. Indeed, PCA revealed clear clustering of control (CNT) and 6-OHDA groups along the first principal component (PC1), accounting for 46.5% of the variance (Fig. 4a). Among all features contributing to PC1, FC data ranked prominently, alongside puncta density and lesion assessments in the CPU, underscoring FC's relevance as a descriptor of disease progression (Fig. 4b). To further validate our findings, we trained a support vector machine (SVM) classifier using the entire dataset and various subsets. The classifier achieved an impressive 89% accuracy when trained with FC data from wide field recordings, while performance dropped to chance level (50%) in the shuffled (bootstrapped) condition, where data was randomly assigned to animals (Fig. 4c). We then examined patterns of correlations within the entire dataset using a correlation matrix (Fig. 4d). This analysis highlighted both positive and negative associations among the measured variables, with notable strong correlations observed between behavioral measures, FC parameters, and synaptic markers. Interestingly, much of the correlation between FC and other parameters was significant for FC data from the right hemisphere, corresponding to the injection site. An intriguing exception to this pattern was observed in the retrosplenial cortex, warranting further investigation (Fig. 4d). Examining specific correlations, we found that WF connectivity in cortical areas was strongly associated with the severity of motor deficits, underscoring its potential as a biomarker for disease progression. This relationship was particularly evident in cortical regions critical for motor processing, where alterations in PV-IN connectivity closely mirrored behavioral impairments (Fig. 4e). Moreover, PV-IN density exhibited a robust correlation with WF connectivity, suggesting that structural changes in inhibitory networks are intrinsically linked to functional connectivity deficits (Fig. 4f). Collectively, these findings indicate that while PV-IN density decreases across hypoconnected cortical regions in the 6-OHDA model, the concurrent reorganization of PV-IN synaptic connectivity—especially in the ipsilateral hemisphere—may represent a compensatory mechanism. This reorganization provides valuable insight into cortical dysfunction in PD models by highlighting the complex interplay between neuronal density and synaptic adaptations in preserving cortical network stability.



710

711

712

713

714

715

716

717

718

719

720

721

722


723

724

Fig. 4 PV-INs Functional Connectivity Predicts Pathology Progression. **a** Scatter plot on the Principal Component space showing the distribution of CNT and 6-OHDA mice on the first and second components. Unpaired t-test $p < 0.0001$. **b** First ten ranked features contributing to the PC1. **c** Average classification accuracy of the SVM classifier in distinguishing CNT and 6-OHDA mice using Leave-One-Out Cross-Validation (LOO-CV). The SVM was trained on different subsets of the dataset plus a bootstrap dataset as control, and accuracy was measured across all Leave-One-Out splits (Wilcoxon Signed Rank Test (against chance: 0.5): All, $p = 0.0039$; Puncta, $p = 0.0039$; Lesion, $p = 0.0039$; Behavior, $p = 0.0039$; WF, $p = 0.0391$). **d** Heat map representing values from the correlation matrix (Pearson correlation) of analysed parameters (bottom triangle), and the significance of each pairwise comparison (top triangle: black box indicates $p < 0.05$). **e-f** Scatter plot and linear regression detailing specific correlations depicted in **D**. In particular, we show the correlation between wide-field data at 28DPL in the MOp-a_R with **e** performance in the behavioral test at 28DPL, and **f** PV density in MOp-p_R (r and p -values are indicated in the figures). All the FC data refer to FC at 28DPL. In blue, CNT $n = 5$ and in orange, 6-OHDA $n = 4$. Mean \pm SEM. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$

Excitatory/Inhibitory Imbalance and Microglial Response in the Motor Cortex Following Dopaminergic Neurodegeneration

725 The striatum communicates indirectly with the motor cortex via basal ganglia circuitry while also
726 receiving direct cortical modulation (Supplementary Fig. 4a). Given our observation of alterations in PV-
727 IN connectivity—crucial for maintaining synchronized cortical activity—we investigated whether
728 dopaminergic loss induces homeostatic changes in excitatory/inhibitory (E/I) balance within the motor
729 cortex. To assess synaptic integrity, we analyzed cortical vesicular markers for both inhibitory (VGAT,
730 Fig. 5a) and excitatory (VGLUT1, Fig. 5c; VGLUT2, Fig. 5e) neurotransmission. Specifically, we
731 quantified the mean fluorescence of excitatory and inhibitory terminals impinging on the soma of layer
732 II/III neurons and further examined synaptic integrity by evaluating vesicular markers as puncta-rings
733 surrounding the cell body. Our findings revealed a pronounced E/I imbalance in the cortex of 6-OHDA-
734 lesioned mice, characterized by significant alterations in the density of these synaptic markers,
735 highlighting potential compensatory mechanisms in response to dopaminergic degeneration.
736 For VGAT, expression levels remained stable, with no significant changes observed, suggesting that
737 inhibitory neurotransmission, represented by VGAT puncta-ring density, was unaffected by
738 dopaminergic loss at the group level. Interhemispheric analysis of anti-VGAT fluorescence mean values
739 confirmed this, showing no significant interaction between the animal groups and hemispheres (Fig.
740 5b). In contrast, for VGLUT1, a significant increase was observed in the ipsilateral hemisphere,
741 suggesting that excitatory synaptic transmission was globally enhanced following dopaminergic lesion.
742 The interhemispheric comparison further reinforced this trend, with pronounced differences observed
743 in the ipsilateral hemisphere of the 6-OHDA group compared to controls (Fig. 5d). Similarly, VGLUT2
744 expression was significantly upregulated in ipsilateral (Fig. 5f, highlighting that the E/I imbalance in the
745 6-OHDA model is largely driven by elevated mean fluorescence of puncta-rings in the ipsilateral
746 hemisphere. These findings suggest an adaptive response to the loss of dopaminergic input,
747 characterized by a pronounced E/I imbalance, likely aimed at compensating for the reduced inhibitory
748 influence in the injured cortex.
749 These findings suggest that the loss of dopaminergic input triggers an adaptive response in the motor
750 cortex, characterized by a pronounced E/I imbalance, likely aimed at compensating for the reduced
751 dopaminergic and altered PV-IN influence in the injured hemisphere. Given the crucial role of microglial
752 in synaptic remodeling, we further examined their involvement in these cortical alterations. As the brain's
753 resident phagocytes, microglia actively remove dead and dying neurons, as well as synapses [31]. In
754 PD and related models like the 6-OHDA lesion, microglial activation often parallels dopaminergic neuron
755 degeneration and is thought to exacerbate or even trigger pathological changes in the cortex [32, 33].
756 Given microglia's pivotal role in synaptic remodeling especially during brain injury [34–36], we thus
757 investigated their role in the observed synaptic modulation in 6-OHDA treated mice. First, we analysed
758 microglial density in cortical areas with identified connectivity deficits and observed no significant
759 changes in the primary motor cortex (M1, Supplementary Fig. 4b), secondary motor cortex (M2,
760 Supplementary Fig. 4c), and somatosensory barrel field (S1BF, Supplementary Fig. 4d).
761 Then, we proceeded to quantify microglial phagocytic ability using CD68 as a marker (Fig. 5g). CD68
762 is a lysosomal and endosomal marker associated with phagocytosis, specifically expressed by
763 macrophages, including Iba1-positive microglia in the CNS. [37] Interestingly, we found an increase in
764 CD68 in microglia in the ipsilateral cortex of 6-OHDA treated mice, suggesting an enhanced microglia
765 engagement in phagocytic activity (Fig. 5h). Additionally, there was an increased engulfment of
766 VGLUT1 by microglia (Fig. 5i). This suggests that microglia are actively participating in the removal of
767 synaptic components, which may be a response to neuronal damage and synaptic remodeling
768 associated with dopaminergic degeneration.



769
770
771
772
773
774
775
776
777
778
779
780
781
782

Fig. 5 Modulation of excitatory and inhibitory transporters and microglia activation after 6-OHDA injection. **a** VGAT puncta-rings analysis. Magnified view of the primary motor cortex stained with anti-VGAT for control (in blue, CNT n=8) and 6-OHDA (in orange, 6-OHDA n=13) groups. Scale bar: 20 µm. **b** Interhemispheric analysis of anti-VGAT fluorescence mean values of puncta-rings around cell bodies per animal in control and 6-OHDA group, calculated in mean fluorescence of puncta-rings around cell bodies. Data from three fields of view per three brain sections n=72 cells for each dataset and CNT animals n=8 vs 6-OHDA animals n=13 were analysed. Two-way ANOVA with Sidak's multiple comparisons test $F_{Groups \times Hemisphere} (1, 38) = 0.01178$ $p=0.9144$, $F_{Groups} (1, 38) = 10.58$ $p=0.0024$, $F_{Hemisphere} (1, 38) = 3.048$ $p=0.00889$. **c** VGLUT1 puncta-rings analysis in control (in blue, CNT n=8) and 6-OHDA (in orange, 6-OHDA n=13) groups. Magnified view of the primary motor cortex stained with anti-VGLUT1. Scale bar: 20 µm. **d** Interhemispheric analysis of anti-VGLUT1 fluorescence mean values of puncta-rings in control and 6-OHDA group. Data from three fields of view per three brain sections n=72 cells for each dataset and CNT animals n=8 vs 6-OHDA animals n=13 were analysed. Two-way ANOVA with Sidak's multiple comparisons test $F_{Groups \times Hemisphere} (1, 38) = 26.21$ $p<0.0001$, $F_{Groups} (1, 38) = 5.374$ $p=0.026$, $F_{Hemisphere} (1, 38) = 40.01$ $p<0.0001$; ipsi 6-OHDA vs CNT $p<0.0001$; 6-OHDA vs CNT ipsi $p<0.0001$. **e** VGLUT2 puncta-rings analysis in control (in blue, CNT n=8) and 6-OHDA (in orange, 6-OHDA n=13) groups. Magnified view of

783 the primary motor cortex stained with anti-VGLUT2. Scale bar: 20 μ m. **f** Interhemispheric analysis of anti-VGLUT2 fluorescence
784 mean values of puncta-rings in control and 6-OHDA group. Data from three fields of view per three brain sections n=72 cells for
785 each dataset and CNT animals n=8 vs 6-OHDA animals n=13 were analysed. Two-way ANOVA with Sidak's multiple comparisons
786 test $F_{\text{Groups} \times \text{Hemisphere}}(1, 38) = 27.21$ $p < 0.0001$, $F_{\text{Groups}}(1, 38) = 64.94$ $p < 0.0001$, $F_{\text{Hemisphere}}(1, 38) = 36.56$ $p < 0.0001$; contra vs ipsi
787 6-OHDA $p < 0.0001$; 6-OHDA vs CNT ipsi $p < 0.0001$. **g-i** Phagocytosis analysis of Iba1-positive cells in the primary motor cortex.
788 **g** Representative tridimensional surface analysis of Iba1, CD68 and VGLUT1 markers in the primary motor cortex stained with
789 anti-Iba1, anti-CD68 and anti-VGLUT1. Scale bar: 7 μ m. **h** Interhemispheric analysis of phagosome volume (CD68+) inside Iba1+
790 cells. n=60 cells for each dataset and CNT animals n=4 vs 6-OHDA animals n=5 were analysed. Two-way ANOVA with Sidak's
791 multiple comparisons test $F_{\text{Groups} \times \text{Hemisphere}}(1, 228) = 9.03$ $p = 0.0030$, $F_{\text{Groups}}(1, 228) = 25.85$ $p < 0.0001$, $F_{\text{Hemisphere}}(1, 228) = 26.08$
792 $p < 0.0001$; contra vs ipsi 6-OHDA $p < 0.0001$; 6-OHDA vs CNT ipsi $p < 0.0001$. **i** Interhemispheric analysis of VGLUT1 engulfment
793 inside CD68 volume, normalized on the total amount of VGLUT1 in the field. n=60 cells for each dataset and CNT animals n=4
794 vs 5 6-OHDA animals n=5 were analysed. Two-way ANOVA with Sidak's multiple comparisons test $F_{\text{Groups}}(1, 228) = 5.00$ $p = 0.026$;
795 6-OHDA vs CNT ipsi $p = 0.053$.

796 Mean \pm SEM. * $p \leq 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. See also Supplementary Figure 4 and Supplementary Table 5.

797

798 DISCUSSION

799 This study provides compelling evidence that subcortical dopaminergic degeneration in a 6-OHDA
800 induced Parkinson's disease model [1, 38], significantly impacts not only cortico-striatal
801 electrophysiological coupling but also functional and anatomical cortical features related to the inhibitory
802 system, specifically Parvalbumin-positive interneurons (PV-INs). Through a combination of
803 electrophysiological recordings, wide-field calcium imaging, and histological analyses, we uncovered a
804 remodelling mechanism of cortical plasticity involving PV-INs in response to nigrostriatal degeneration.
805 Electrophysiological analysis of both the striatum and motor cortex, focusing on their functional coupling
806 in resting state, revealed a significant increase in striatal delta band activity in 6-OHDA mice, consistent
807 with previous studies (Fig. 1c) [39, 40]. Although direct changes in motor cortex activity at rest were not
808 observed, we identified a progressive increase in cortico-striatal coherence in the delta band as the
809 pathology advanced (Fig. 1f). Interestingly, the rise in striatal delta power alone does not fully account
810 for the observed increased cortico-striatal coherence, as these phenomena can occur independently
811 though related [41]. In fact, elevated striatal delta power reflects increased local oscillatory activity,
812 whereas increased coherence indicates stronger functional connectivity or phase alignment between
813 the cortex and striatum. This distinction suggests that the 6-OHDA-induced neurodegeneration drives
814 pathological entrainment of cortico-striatal communication, potentially contributing to disrupted cortical
815 network dynamics in Parkinson's disease.

816 During voluntary movement, we instead observed stark differences in spectral modulation between 6-
817 OHDA-treated and control mice. In the striatum of 6-OHDA mice, spectral modulation was essentially
818 absent from the earliest recording stages, indicating that the neurotoxin rapidly disrupts movement-
819 related subcortical oscillatory activity (Fig. 1i). In contrast, control mice exhibited robust movement-
820 related spectral modulation in the striatum during the voluntary retraction task, underscoring the early
821 impact of 6-OHDA on striatal function (Fig. 1j).

822 Interestingly, in control mice, spectral modulation gradually decreased in both the striatum and cortex
823 over the recording weeks (Fig. 1i, j). This decline may reflect two factors: a potential loss of electrode
824 signal quality over time, as is common in chronic recordings [42], and a possible habituation effect to
825 the task, where repeated exposure reduces the neuronal response [43]. Despite this overall trend, we
826 observed an opposing pattern in the high-gamma range in the motor cortex of 6-OHDA mice, where
827 high-gamma power progressively increased throughout recording weeks (Fig. 1o). This heightened
828 high-gamma modulation may reflect network hypersynchrony or enhanced firing near the electrode tip
829 [44], potentially linked to reduced parvalbumin-positive interneurons (PV-INs) signaling. These findings
830 underscore the dual role of cortical and subcortical dynamics in PD pathology, where the motor cortex
831 undergoes spectral changes to compensate for striatal dysfunction. However, the progressive
832 divergence in spectral patterns, particularly the rise in high-gamma modulation during movement,
833 highlights the maladaptive nature of these compensations.

834 Previous research showed that PV-INs are key regulators of cortical inhibition control and suggested
835 that gamma oscillations regulated by PV-INs promote synaptic plasticity in cortical motor areas [7, 11,
836 29, 45–47]. We therefore longitudinally investigated alterations in PV-INs cortical network using wide-
837 field calcium imaging (Fig. 2). Electrophysiological and imaging analyses revealed that while the

838 pathological phenotype remains stable over time (Supplementary Fig. 1f), FC undergoes progressive
839 deterioration with the most pronounced alterations emerging at 28 days post-lesion (Fig. 2f). Critically,
840 inter-hemispheric connectivity was strongly affected already at early time points (Fig. 2h), indicating that
841 dopaminergic loss impacts cortical communication between hemispheres more than intra-hemispheric
842 connections. Although our findings suggest a disruption of inter-hemispheric communication, further
843 investigation into PV-IN density, morphology and synaptic connectivity (Fig. 3) provides critical insights
844 into the role of the healthy hemisphere in the compensatory mechanisms that reshape PV-IN cortical
845 network. Despite a symmetric reduction in PV-IN density across hemispheres and cortical layers (Fig.
846 3b-d), we observed a selective upregulation of inhibitory synaptic output in the ipsilateral hemisphere
847 to the lesion, particularly strong in the primary and secondary motor cortex (Fig. 3i-k). At the same time,
848 3D dendritic reconstructions and Sholl analysis of PV-INs in the primary motor cortex revealed a
849 significant reduction in dendritic branching in layers 2/3 PV-INs of the ipsilateral hemisphere (Fig. 3n).
850 In contrast, PV-INs in the contralateral hemisphere exhibit increased dendritic branch complexity (Fig.
851 3n). These findings suggest a shift in inter-hemispheric control, with the contralateral hemisphere
852 compensating for functional deficits by enhancing long-range connectivity and synaptic contacts.
853 PV-INs in cortical layers 2/3 possess relatively long axons that contact excitatory (pyramidal) and PV+
854 cells, facilitating the synchronization of gamma oscillations[12]. These synchronized oscillations are
855 integral to motor planning and execution and suggest a potential indirect influence on interhemispheric
856 communication through long-range pyramidal neurons, particularly in layers 2/3. [48] Such changes in
857 PV-IN distribution and synaptic activity highlight a broader disruption in the inhibitory network, extending
858 beyond PV-IN cell bodies to their synaptic targets. This disruption likely compromises inhibitory control
859 mechanisms, impairing the generation and maintenance of gamma oscillations critical for cortical
860 network stability. These structural alterations align with functional connectivity deficits, emphasizing the
861 essential role of PV-IN integrity in maintaining cortical stability. Moreover, our findings contribute to a
862 broader understanding of cortical dysfunction in PD models by highlighting the intricate relationship
863 between neuronal density and synaptic adjustments in maintaining cortical network stability.
864 Overall, our results suggest that dopaminergic loss does not lead solely to a breakdown of PV-INs
865 cortico-cortical communication but instead triggers an asymmetric gain-of-function adaptation in the
866 contralateral hemisphere, likely as a mechanism to offset motor and sensory deficits.
867 Atrophy of dendrite branching points in the ipsilateral hemisphere of 6-OHDA mice and the structural
868 change following degeneration of the dopaminergic system and consequent decrease of subcortical
869 innervation to motor cortex is compensated with an enhanced synaptic strength. Globally, the observed
870 symmetric reductions in PV cell bodies could reflect a widespread vulnerability of these neurons.
871 Locally, in the ipsilateral hemisphere, the reduced connectivity among PV-PV circuits and the decrease
872 in dendritic complexity may limit PV-IN functionality. This could necessitate compensatory synaptic
873 remodeling, such as increased PV-to-non-PV connections. These changes might contribute to cortical
874 network instability and altered oscillatory activity, potentially exacerbating motor deficits characteristic
875 of Parkinson's disease.
876 The observed changes are consistent with previous reports of PV-IN vulnerability in neurodegenerative
877 conditions [49, 50] and underscore their importance as therapeutic targets in PD. The loss of PV-INs,
878 which play a central role in maintaining excitatory/inhibitory balance, may exacerbate cortical
879 hyperexcitability and contribute to the E/I imbalance observed in this study. By impairing gamma
880 oscillations and long-range synchrony, PV-IN reductions likely disrupt motor planning and execution,
881 key features of PD pathology. Future therapeutic strategies should focus on restoring PV-IN function or
882 compensating for their loss to stabilize cortical networks and improve motor outcomes in PD. Indeed,
883 histological analysis revealed a profound imbalance between excitatory and inhibitory synaptic markers
884 [51, 52]. with increased excitatory drive likely compensating for dopaminergic loss in primary motor
885 cortex. While VGAT levels (inhibitory synaptic marker) remained stable, VGLUT1 and VGLUT2
886 (excitatory synaptic markers) were significantly upregulated. This imbalance exacerbates cortical
887 hyperactivity and disrupts normal motor processing. This suggests that cortical hyperactivity emerges
888 as a compensatory response to subcortical degeneration. Interestingly, this excitatory/inhibitory
889 imbalance cannot be attributed to dopaminergic degeneration alone, as the motor cortex does not

890 receive direct dopaminergic innervation [53, 54]. Instead, we propose glutamatergic modulation plays
891 a critical role, as the primary motor cortex integrates subcortical inputs and modulates striatal
892 dopaminergic neurons [55–57].

893 In addition to neuronal and synaptic changes, we observed significant alterations in microglial activity
894 in the motor cortex. Microglial cells displayed increased phagocytic activity, suggesting an ongoing
895 neuroinflammatory response. Interestingly, we found an increase in VGLUT1 phagocytosis by
896 microglia, which is captivating since total VGLUT1 in the tissue seems to be elevated. This apparent
897 paradox may be explained by a compensatory upregulation of excitatory synapse formation in response
898 to increased microglial activity, suggesting that neurons might bolster synaptic connectivity to offset
899 potential losses. Alternatively, the accumulation of VGLUT1 could indicate that engulfed material is not
900 fully degraded, thereby contributing to the overall increase. These findings underscore a dynamic
901 interplay between synaptic remodeling and microglial clearance, hinting that heightened synaptic
902 turnover may underlie the observed phenomena. Such a scenario suggests a dynamic interplay
903 between compensatory synaptic remodeling and neuroinflammatory processes, exacerbating neuronal
904 damage while attempting to preserve cortical functionality [58–60]. While this response may initially aim
905 to clear debris and maintain homeostasis, excessive microglial activation could exacerbate cortical
906 dysfunction and contribute to disease progression. This evidence underscores the need to address both
907 neuronal and microglial contributions in future therapeutic strategies.

908 Collectively, our findings point to a cascade of maladaptive cortical processes initiated by subcortical
909 dopaminergic degeneration. High-gamma cortical hypersynchrony and pathological striatal delta
910 modulation disrupt cortico-striatal communication, impairing motor control. Reduced PV-IN density and
911 connectivity destabilize cortical networks, leading to hyperexcitability and compensatory plasticity, with
912 hyper-synchronized activity and a possible overcoming of the contralateral hemisphere. PV alterations
913 lead to E/I imbalance and microglial phagocytosis amplifies synaptic turnover, linking
914 neuroinflammation to synaptic modelling and further circuit dysfunction. This cascade underscores the
915 complex interplay between neuronal, synaptic, and inflammatory mechanisms in PD pathology. Taken
916 together, these disruptions in local and global network dynamics contribute to motor deficits in PD. The
917 progressive nature of these alterations emphasizes the importance of early intervention to prevent or
918 mitigate cortical dysfunction.

919 Importantly, this study identifies the motor cortex as a critical site for therapeutic intervention in PD. Our
920 results suggest that wide-field calcium imaging could serve as a valuable biomarker for monitoring
921 disease progression and evaluating therapeutic efficacy. The observed functional reorganization and
922 both electrophysiological and synaptic imbalances provide critical insights into cortical compensatory
923 mechanisms, reinforcing the need for therapeutic strategies targeting the motor cortex. Non-invasive
924 approaches, such as transcranial alternating current stimulation, might offer promise for modulating
925 abnormal cortical activity and synchronizing cortico-striatal circuits [61]. Additionally, altered microglial
926 activity suggests that neurotrophic factors, such as nerve growth factor (NGF), may help restore
927 neuronal function and mitigate neuroinflammation [62]. In conclusion, addressing motor cortex
928 dysfunction is essential for slowing PD progression and improving motor function. A combination of
929 approaches, such as brain stimulation to correct electrophysiological abnormalities and NGF to support
930 neuronal survival, might offer a synergistic path forward.

931

932 ***Limitations of the study***

933 While this study provides valuable insights into the 6-OHDA mouse model of Parkinson's disease,
934 several limitations must be acknowledged. The 6-OHDA model effectively replicates key aspects of
935 dopaminergic neuron loss; however, it might not fully encompass the progressive and bilateral nature
936 of human PD. In this study, we opted for a unilateral lesion approach to establish a well-characterized
937 model of the pathology. Nevertheless, exploring bilateral lesion in future studies could be useful to
938 further assess therapeutic efficacy in a more widespread neurodegenerative context, improving
939 translational relevance to clinical settings.

940 Additionally, this study primarily focuses on motor deficits, while non-motor symptoms, such as cognitive
941 and emotional dysfunctions, remain unexplored. Since our objective was to investigate the motor cortex

942 as a potential therapeutic target, we employed a model that effectively recapitulates motor symptoms.
943 However, incorporating assessments of non-motor dysfunctions in future studies might provide a more
944 comprehensive understanding of the disease.

945 Furthermore, longer-term studies could be valuable to fully understand the chronic effects of
946 dopaminergic degeneration. Another consideration is the interpretation of cortico-striatal dynamics, as
947 this study does not allow for a direct causal relationship between the cortex and striatum to be
948 established. This suggests the need for further exploration of multisynaptic pathways or shared synaptic
949 drives that might explain these findings.

950 Finally, although the results highlight potential therapeutic targets, such as non-invasive brain
951 stimulation and nerve growth factor (NGF), further investigations in more complex models or clinical
952 settings would be necessary to validate these interventions before they can be considered for
953 translation to human therapies.

954

955 **Conclusions**

956 Our study highlights the critical role of cortical PV-INs, oscillatory dynamics, and neuroinflammatory
957 processes in PD. The findings reveal that delta and gamma oscillations represent key markers of
958 cortico-striatal dysfunction. PV-INs serve as central regulators of cortical stability, with their dysfunction
959 exacerbating E/I imbalance and motor impairments. Synaptic remodeling and microglial activity
960 contribute to the pathological adaptations, linking neuroinflammation to neuronal damage. These
961 insights offer a framework for understanding PD-related cortical changes and suggest potential
962 therapeutic targets. Interventions aimed at restoring PV-IN functionality, modulating oscillatory activity,
963 or mitigating neuroinflammation could provide novel strategies to alleviate motor and cognitive
964 symptoms in PD. Future research should explore the temporal dynamics of these processes and their
965 interactions to develop targeted therapies aimed at improving clinical outcomes and slowing disease
966 progression.

967

968 **FUNDING**

969 Fondo Beneficenza Intesa San Paolo n. B/2022/0193, Project “ONDA”, Project Manager: Cristina
970 Spalletti

971

972 **RESOURCE AVAILABILITY**

973 **Lead contact**

974 Further information and requests for resources and reagents should be directed to and will be fulfilled
975 by the lead contact, Cristina Spalletti (cristina.spalletti@in.cnr.it).

976 **Materials availability**

977 All source data are accessible in a public database.

978

979 **ACKNOWLEDGMENTS**

980 We thank Francesca Biondi (CNR Pisa) for the excellent animal care, Maria Pasquini, Elena Novelli
981 and Renzo di Renzo for technical support with imaging and informatics.

982

983 **AUTHOR CONTRIBUTIONS**

984 Conceptualization, C.S., A.L.A.M., A.Maz., and S.C.; methodology, C.S., A.L.A.M., A.Maz., and S.C.;
985 investigation, A.Mi., F.M., A.Mar., E.M., E.C., A.T., N.M., A.Maz., A.L.A.M., C.S., and S.C.; writing –
986 original draft, A.Mi., E.M., N.M., A.Maz., A.L.A.M., S.C., and C.S.; writing – review & editing: A.Mi., E.M.,
987 E.C., A.T., N.M., A.Maz., A.L.A.M., S.C., and C.S.; funding acquisition, C.S., A.L.A.M., and A.Maz.;
988 resources, C.S., A.L.A.M., and A.Maz.; supervision, C.S., A.L.A.M., A.Maz., and S.C.

989

990 **DECLARATION OF INTERESTS**

991 Authors declare that they have no competing interests.

992

993 **SUPPLEMENTAL INFORMATION**

994 **Document S1. Figures S1–S4 and Table S1-S5.**

995

996 **REFERENCES**

- 997 1. Kouli A, Torsney KM, Kuan W-L (2018) Parkinson's Disease: Etiology, Neuropathology, and
998 Pathogenesis. Codon Publications
- 999 2. DeMaagd G, Philip A (2015) Parkinson's disease and its management: Part 1: Disease entity,
1000 risk factors, pathophysiology, clinical presentation, and diagnosis. *P T* 40:504–532
- 1001 3. Moustafa AA, Chakravarthy S, Phillips JR, et al (2016) Motor symptoms in Parkinson's disease: A
1002 unified framework. *Neurosci Biobehav Rev* 68:727–740.
1003 <https://doi.org/10.1016/j.neubiorev.2016.07.010>
- 1004 4. Lindenbach D, Bishop C (2013) Critical involvement of the motor cortex in the pathophysiology
1005 and treatment of Parkinson's disease. *Neurosci Biobehav Rev* 37:2737–2750.
1006 <https://doi.org/10.1016/j.neubiorev.2013.09.008>
- 1007 5. Magrinelli F, Picelli A, Tocco P, et al (2016) Pathophysiology of motor dysfunction in Parkinson's
1008 disease as the rationale for drug treatment and rehabilitation. *Parkinsons Dis* 2016:9832839.
1009 <https://doi.org/10.1155/2016/9832839>
- 1010 6. Ferrazzoli D, Ortelli P, Madeo G, et al (2018) Basal ganglia and beyond: The interplay between
1011 motor and cognitive aspects in Parkinson's disease rehabilitation. *Neurosci Biobehav Rev*
1012 90:294–308. <https://doi.org/10.1016/j.neubiorev.2018.05.007>
- 1013 7. Nowak M, Zich C, Stagg CJ (2018) Motor cortical gamma oscillations: What have we learnt and
1014 where are we headed? *Curr Behav Neurosci Rep* 5:136–142. [https://doi.org/10.1007/s40473-](https://doi.org/10.1007/s40473-018-0151-z)
1015 [018-0151-z](https://doi.org/10.1007/s40473-018-0151-z)
- 1016 8. Guerra A, Asci F, D'Onofrio V, et al (2020) Enhancing gamma oscillations restores primary motor
1017 cortex plasticity in Parkinson's disease. *J Neurosci* 40:4788–4796.
1018 <https://doi.org/10.1523/JNEUROSCI.0357-20.2020>
- 1019 9. Buzsáki G, Wang X-J (2012) Mechanisms of gamma oscillations. *Annu Rev Neurosci* 35:203–
1020 225. <https://doi.org/10.1146/annurev-neuro-062111-150444>
- 1021 10. Hijazi S, Smit AB, van Kesteren RE (2023) Fast-spiking parvalbumin-positive interneurons in
1022 brain physiology and Alzheimer's disease. *Mol Psychiatry* 28:4954–4967.
1023 <https://doi.org/10.1038/s41380-023-02168-y>
- 1024 11. Rupert DD, Shea SD (2022) Parvalbumin-positive interneurons regulate cortical sensory plasticity
1025 in adulthood and development through shared mechanisms. *Front Neural Circuits* 16:886629.
1026 <https://doi.org/10.3389/fncir.2022.886629>
- 1027 12. Milicevic KD, Barbeau BL, Lovic DD, et al (2024) Physiological features of parvalbumin-
1028 expressing GABAergic interneurons contributing to high-frequency oscillations in the cerebral
1029 cortex. *Curr Res Neurobiol* 6:100121. <https://doi.org/10.1016/j.crneur.2023.100121>
- 1030 13. He Q, Zhang X, Yang H, et al (2024) Early synaptic dysfunction of striatal parvalbumin
1031 interneurons in a mouse model of Parkinson's disease. *iScience* 27:111253.
1032 <https://doi.org/10.1016/j.isci.2024.111253>
- 1033 14. Masini D, Plewnia C, Bertho M, et al (2021) A Guide to the Generation of a 6-Hydroxydopamine
1034 Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms. *Biomedicines* 9.:
1035 <https://doi.org/10.3390/biomedicines9060598>
- 1036 15. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in
1037 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal
1038 function. *Neurobiol Dis* 16:110–123. <https://doi.org/10.1016/j.nbd.2004.01.007>

- 1039 16. Grealish S, Mattsson B, Draxler P, Björklund A (2010) Characterisation of behavioural and
1040 neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model
1041 of Parkinson's disease. *Eur J Neurosci* 31:2266–2278. [https://doi.org/10.1111/j.1460-](https://doi.org/10.1111/j.1460-9568.2010.07265.x)
1042 9568.2010.07265.x
- 1043 17. Spalletti C, Lai S, Mainardi M, et al (2014) A robotic system for quantitative assessment and
1044 poststroke training of forelimb retraction in mice. *Neurorehabil Neural Repair* 28:188–196.
1045 <https://doi.org/10.1177/1545968313506520>
- 1046 18. Lai S, Panarese A, Spalletti C, et al (2015) Quantitative kinematic characterization of reaching
1047 impairments in mice after a stroke. *Neurorehabil Neural Repair* 29:382–392.
1048 <https://doi.org/10.1177/1545968314545174>
- 1049 19. Pasquini M, Lai S, Spalletti C, et al (2018) A Robotic System for Adaptive Training and Function
1050 Assessment of Forelimb Retraction in Mice. *IEEE Trans Neural Syst Rehabil Eng* 26:1803–1812.
1051 <https://doi.org/10.1109/TNSRE.2018.2864279>
- 1052 20. Minetti A (2024) Unlocking the potential of adeno-associated virus in neuroscience: a brief
1053 review. *Mol Biol Rep* 51:563. <https://doi.org/10.1007/s11033-024-09521-6>
- 1054 21. Montagni E, Resta F, Tort-Colet N, et al (2024) Mapping brain state-dependent sensory
1055 responses across the mouse cortex. *iScience* 27:109692.
1056 <https://doi.org/10.1016/j.isci.2024.109692>
- 1057 22. Conti E, Allegra Mascaro AL, Pavone FS (2019) Large Scale Double-Path Illumination System
1058 with Split Field of View for the All-Optical Study of Inter-and Intra-Hemispheric Functional
1059 Connectivity on Mice. *Methods Protoc* 2.: <https://doi.org/10.3390/mps2010011>
- 1060 23. Zalesky A, Fornito A, Bullmore ET (2010) Network-based statistic: identifying differences in brain
1061 networks. *Neuroimage* 53:1197–1207. <https://doi.org/10.1016/j.neuroimage.2010.06.041>
- 1062 24. Nakai N, Sato M, Yamashita O, et al (2023) Virtual reality-based real-time imaging reveals
1063 abnormal cortical dynamics during behavioral transitions in a mouse model of autism. *Cell Rep*
1064 42:112258. <https://doi.org/10.1016/j.celrep.2023.112258>
- 1065 25. Schallert T, Bland ST, Leasure JL, et al (2000) Motor rehabilitation, use-related neural events,
1066 and reorganization of the brain after injury. In: *Cerebral Reorganization of Function After Brain*
1067 *Damage*. Oxford University Press New York, NY, pp 145–167
- 1068 26. Bonito-Oliva A, Pignatelli M, Spigolon G, et al (2014) Cognitive impairment and dentate gyrus
1069 synaptic dysfunction in experimental parkinsonism. *Biol Psychiatry* 75:701–710.
1070 <https://doi.org/10.1016/j.biopsych.2013.02.015>
- 1071 27. Spalletti C, Alia C, Lai S, et al (2017) Combining robotic training and inactivation of the healthy
1072 hemisphere restores pre-stroke motor patterns in mice. *Elife* 6.:
1073 <https://doi.org/10.7554/elife.28662>
- 1074 28. Hadler MD, Tzilivaki A, Schmitz D, et al (2024) Gamma oscillation plasticity is mediated via
1075 parvalbumin interneurons. *Sci Adv* 10:eadj7427. <https://doi.org/10.1126/sciadv.adj7427>
- 1076 29. Kriener B, Hu H, Vervaeke K (2022) Parvalbumin interneuron dendrites enhance gamma
1077 oscillations. *Cell Rep* 39:110948. <https://doi.org/10.1016/j.celrep.2022.110948>
- 1078 30. Cho KKA, Davidson TJ, Bouvier G, et al (2020) Cross-hemispheric gamma synchrony between
1079 prefrontal parvalbumin interneurons supports behavioral adaptation during rule shift learning. *Nat*
1080 *Neurosci* 23:892–902. <https://doi.org/10.1038/s41593-020-0647-1>
- 1081 31. Hong S, Stevens B (2016) Microglia: Phagocytosing to clear, sculpt, and eliminate. *Dev Cell*
1082 38:126–128. <https://doi.org/10.1016/j.devcel.2016.07.006>
- 1083 32. Isik S, Yeman Kiyak B, Akbayir R, et al (2023) Microglia mediated neuroinflammation in
1084 Parkinson's Disease. *Cells* 12:1012. <https://doi.org/10.3390/cells12071012>

- 1085 33. Zhang W, Xiao D, Mao Q, Xia H (2023) Role of neuroinflammation in neurodegeneration
1086 development. *Signal Transduct Target Ther* 8:267. <https://doi.org/10.1038/s41392-023-01486-5>
- 1087 34. Cangalaya C, Wegmann S, Sun W, et al (2023) Real-time mechanisms of exacerbated synaptic
1088 remodeling by microglia in acute models of systemic inflammation and tauopathy. *Brain Behav*
1089 *Immun* 110:245–259. <https://doi.org/10.1016/j.bbi.2023.02.023>
- 1090 35. Salter MW, Stevens B (2017) Microglia emerge as central players in brain disease. *Nat Med*
1091 23:1018–1027. <https://doi.org/10.1038/nm.4397>
- 1092 36. Krukowski K, Nolan A, Becker M, et al (2021) Novel microglia-mediated mechanisms underlying
1093 synaptic loss and cognitive impairment after traumatic brain injury. *Brain Behav Immun* 98:122–
1094 135. <https://doi.org/10.1016/j.bbi.2021.08.210>
- 1095 37. Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker
1096 related to lysosomal glycoproteins. *Blood* 81:1607–1613.
1097 <https://doi.org/10.1182/blood.v81.6.1607.1607>
- 1098 38. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease.
1099 *Neurotox Res* 11:151–167. <https://doi.org/10.1007/BF03033565>
- 1100 39. Whalen TC, Willard AM, Rubin JE, Gittis AH (2020) Delta oscillations are a robust biomarker of
1101 dopamine depletion severity and motor dysfunction in awake mice. *J Neurophysiol* 124:312–329.
1102 <https://doi.org/10.1152/jn.00158.2020>
- 1103 40. Chen H, Lei H, Xu Q (2018) Neuronal activity pattern defects in the striatum in awake mouse
1104 model of Parkinson's disease. *Behav Brain Res* 341:135–145.
1105 <https://doi.org/10.1016/j.bbr.2017.12.018>
- 1106 41. Ohara S, Mima T, Baba K, et al (2001) Increased synchronization of cortical oscillatory activities
1107 between human supplementary motor and primary sensorimotor areas during voluntary
1108 movements. *J Neurosci* 21:9377–9386. <https://doi.org/10.1523/jneurosci.21-23-09377.2001>
- 1109 42. Barrese JC, Rao N, Paroo K, et al (2013) Failure mode analysis of silicon-based intracortical
1110 microelectrode arrays in non-human primates. *J Neural Eng* 10:066014.
1111 <https://doi.org/10.1088/1741-2560/10/6/066014>
- 1112 43. Grissom N, Bhatnagar S (2009) Habituation to repeated stress: get used to it. *Neurobiol Learn*
1113 *Mem* 92:215–224. <https://doi.org/10.1016/j.nlm.2008.07.001>
- 1114 44. Meneghetti N, Vannini E, Mazzoni A (2024) Rodents' visual gamma as a biomarker of
1115 pathological neural conditions. *J Physiol* 602:1017–1048. <https://doi.org/10.1113/JP283858>
- 1116 45. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009) Parvalbumin neurons and gamma rhythms
1117 enhance cortical circuit performance. *Nature* 459:698–702. <https://doi.org/10.1038/nature07991>
- 1118 46. Izaki Y, Akema T (2008) Gamma-band power elevation of prefrontal local field potential after
1119 posterior dorsal hippocampus-prefrontal long-term potentiation induction in anesthetized rats. *Exp*
1120 *Brain Res* 184:249–253. <https://doi.org/10.1007/s00221-007-1098-6>
- 1121 47. Vignozzi L, Macchi F, Montagni E, et al (2024) Combining Gamma neuromodulation and robotic
1122 rehabilitation restores parvalbumin-mediated Gamma function and boosts motor recovery in
1123 stroke mice. *bioRxiv*
- 1124 48. Shepherd GMG (2013) Corticostriatal connectivity and its role in disease. *Nat Rev Neurosci*
1125 14:278–291. <https://doi.org/10.1038/nrn3469>
- 1126 49. Ruden JB, Dugan LL, Konradi C (2021) Parvalbumin interneuron vulnerability and brain
1127 disorders. *Neuropsychopharmacology* 46:279–287. <https://doi.org/10.1038/s41386-020-0778-9>
- 1128 50. Smeralda CL, Pandit S, Turrini S, et al (2024) The role of parvalbumin interneuron dysfunction
1129 across neurodegenerative dementias. *Ageing Res Rev* 101:102509.

- 1130 <https://doi.org/10.1016/j.arr.2024.102509>
- 1131 51. Lu J-S, Chen Q-Y, Chen X, et al (2021) Cellular and synaptic mechanisms for Parkinson's
1132 disease-related chronic pain. *Mol Pain* 17:1744806921999025.
1133 <https://doi.org/10.1177/1744806921999025>
- 1134 52. Mallet N, Delgado L, Chazalon M, et al (2019) Cellular and Synaptic Dysfunctions in Parkinson's
1135 Disease: Stepping out of the Striatum. *Cells* 8.: <https://doi.org/10.3390/cells8091005>
- 1136 53. Bjorklund A (1984) Dopamine-containing systems in the CNS. *Handbook of chemical*
1137 *neuroanatomy: Classical Transmitters in the CNS* 2:55–122
- 1138 54. Björklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an update. *Trends*
1139 *Neurosci* 30:194–202. <https://doi.org/10.1016/j.tins.2007.03.006>
- 1140 55. Luo P, Li A, Zheng Y, et al (2019) Whole brain mapping of long-range direct input to
1141 glutamatergic and GABAergic neurons in motor cortex. *Front Neuroanat* 13:44.
1142 <https://doi.org/10.3389/fnana.2019.00044>
- 1143 56. Gardoni F, Bellone C (2015) Modulation of the glutamatergic transmission by Dopamine: a focus
1144 on Parkinson, Huntington and Addiction diseases. *Front Cell Neurosci* 9:25.
1145 <https://doi.org/10.3389/fncel.2015.00025>
- 1146 57. Jeong M, Kim Y, Kim J, et al (2016) Comparative three-dimensional connectome map of motor
1147 cortical projections in the mouse brain. *Sci Rep* 6:20072. <https://doi.org/10.1038/srep20072>
- 1148 58. Çınar E, Tel BC, Şahin G (2022) Neuroinflammation in Parkinson's Disease and its Treatment
1149 Opportunities. *Balkan Med J* 39:318–333. <https://doi.org/10.4274/balkanmedj.galenos.2022.2022-7-100>
- 1151 59. Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson's disease and its potential as
1152 therapeutic target. *Transl Neurodegener* 4:19. <https://doi.org/10.1186/s40035-015-0042-0>
- 1153 60. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease.
1154 *Parkinsonism Relat Disord* 10 Suppl 1:S3–7. <https://doi.org/10.1016/j.parkreldis.2004.01.005>
- 1155 61. Mattioli F, Magliarella V, D'Antonio S, et al (2024) Non-invasive brain stimulation for patients and
1156 healthy subjects: Current challenges and future perspectives. *J Neurol Sci* 456:122825.
1157 <https://doi.org/10.1016/j.jns.2023.122825>
- 1158 62. Tiberi A, Borgonovo G, Testa G, et al (2024) Reversal of neurological deficits by painless nerve
1159 growth factor in a mouse model of Rett syndrome. *Brain* 147:122–134.
1160 <https://doi.org/10.1093/brain/awad282>